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Abstract 
Parkinson’s disease is the second most common neurodegenerative 
disorder after Alzheimer’s disease and affects about 1% of the population over 
65 years old. This disorder can be both sporadic and familial and some genetic 
forms are due to mutations in SNCA gene, encoding for the protein alpha-
synuclein (aS). 
PD pathological hallmarks are the prominent death of the dopaminergic 
neurons in the substantia nigra pars compacta and the presence of proteins and 
lipid inclusions, termed Lewy’s body (LBs), in the surviving neurons in 
parkinsonian brains. The main constituent of LBs is an aggregated fibrillar -
sheet rich form of aS. aS aggregation process was widely studied in the past 
years: the protein is unfolded in its native state, but in pathological conditions it 
tends to aggregate forming oligomeric species. These oligomers constitute a 
heterogeneous and transient ensemble and rapidly convert into amyloid fibrils 
when they reach a critical concentration. Amyloid fibrils then deposit in LBs 
along with several other proteins and lipids.  
aS aggregation was mainly studied in vitro, but recently more efforts 
were put into the study of this process in cell and animal models, to identify not 
only aS aggregation intermediates, but also the associated toxic mechanism(s) 
that lead to neurons cell death in PD. 
In this thesis two main issues were faced: the study of aS aggregation in 
cells using unconventional methods and the characterization of the effects of the 
family of chaperone-like proteins 14-3-3, on aS aggregation. 
In the first part, two cellular models for the study of aS aggregation 
were set and characterized: the first one is obtained just overexpressing aS and 
allowed the characterization of an ensemble of heterogeneous oligomeric species 
(about 6±4 monomers per oligomer) using a new fluorescence microscopy 
method termed Number and Brightness analysis. These oligomeric species 
induced autophagic lysosomal pathway activation and mitochondrial 
fragmentation in this model.  
The second cellular model provides a method to study aS fibrils and 
larger aggregates in a physiological environment: aS was overexpressed in cells 
 VIII 
 
and aggregation was triggered by introducing in cell cytoplasm recombinant aS 
fibrils fragments, termed seeds. In both cases aS overexpression and aggregation 
cause cellular death, in good agreement with what was previously published by 
others groups. 
The characterization of aS aggregation in cells went further looking at 
the variation in cellular metabolism, possibly induced by mitochondrial damage. 
These changes were quantified measuring NADH fluorescence properties in the 
two models with respect to the control. These results showed that in cells 
presenting aS oligomer or aggregates, NADH fluorescence lifetime and emission 
spectra change, suggesting that these measurements may be used to detect aS 
aggregates in live cells and in vivo using a non-invasive dye-free method. 
The second part of the thesis concerns the ability of 14-3-3 chaperone-
like proteins of interacting with aS and of interfering with aS aggregation 
process rescuing the induced toxicity in cells.  
Among the seven 14-3-3 isoforms, 14-3-3 can re-route aS 
amyloidogenic process in vitro, leading to the formation of curved objects rather 
than aS fibrils. These curved objects have diameters and curvatures that depend 
on 14-3-3  amount in the aggregation assays; moreover, 14-3-3  molecules 
were found in these aggregates, suggesting the formation of a stable complex 
between the two proteins.  When aS amount is too large or seeds are used to 
trigger the aggregation process in vitro, 14-3-3  is not able any more to affect 
aS aggregation and is sequestered into aS fibrils.  
In cell models, 14-3-3  overexpression leads to a rescue when aS was 
only overexpressed, but not when aggregation in cell cytoplasm was triggered by 
seeds. Overexpressed 14-3-3  was found to interact with overexpressed aS 
using image correlation spectroscopy methods (cross raster image correlation 
spectroscopy and cross Number and Brightness analysis), mainly at plasma 
membrane. Moreover, 14-3-3  is sequestered into aggregates when aS 
aggregation is triggered by seeds, highlighting another possible toxic mechanism 
due to aS aggregation. All the results obtained in cells are in good agreement 
with the in vitro results previously reported, further suggesting that 14-3-3 
proteins and  isoform in particular are interesting in aS aggregation frame and 
may be used to interfere in the process to rescue its toxic effects.  
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Riassunto 
La malattina di Parkinson è la seconda malattia neurodegenerative più 
comune dopo il morbo di Alzheimer e colpisce circa l’1% delle popolazione 
sopra i 65 anni di età. Questa malattia può essere sia sporadica che familiare e 
alcune forme genetiche sono dovute a mutazioni nel gene SNCA che codifica per 
la proteina alfa-sinucleina. 
Le caratteristiche patologiche principali della malattia di Parkinson sono 
la morte prevalentemente dei neuroni dopaminergici della substantia nigra pars 
compacta e la presentza di inclusioni proteiche e lipidiche, dette corpi di Lewy, 
nei neuroni che sopravvivono nei cervelli dei pazienti affetti dalla malattia. 
Il componente principale dei corpi di Lewy è una forma di alfa-
sinucleina aggregata, fibrillare e ricca di foglietti beta. Il processo di 
aggregazione di alfa-sinucleina è stato ampiamente studiato negli anni passati: la 
proteina è non strutturata nella sua forma nativa, ma in condizioni patologiche 
tende ad aggregare formando specie oligomeriche. Questi oligomeri 
costituiscono un insieme etereogeneo e transiente e si convertono rapidamente in 
fibrille amiloidi quando raggiungono una concentrazione critica. Le fibrille 
amiloidi di alfa-sinucleina si depositano poi nei corpi di Lewy assieme ad altre 
proteine e lipidi. 
L’aggregazione di alfa-sinucleina è stata principalmente studiata in 
vitro, anche se più recentemente maggiori sforzi sono stati effettuati per 
caratterizzare il processo in modelli cellulari ed animali, per identificare non 
soltanto i diversi prodotti dell’aggregazione, ma anche i meccanismi tossici ad 
essi associati, che causano la morte dei neuroni nei pazienti affetti dalla malattia 
di Parkinson. 
In questa tesi due questioni principali sono state affrontate: lo studio 
dell’aggregazione di alfa-sinucleina in cellule utilizzando metodi non 
convenzionali di microscopia in  fluorescenza e la caratterizzazione degli effetti 
di una famiglia di proteine chaperoniche, le 14-3-3, sul processo di 
aggregazione. 
Nella prima parte, due modelli cellulari per lo studio dell’aggregazione 
di alfa-sinucleina sono stati approntati e caratterizzati: il primo viene ottenuto 
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sovraesprimento soltanto alfa-sinucleina e ha permesso la caratterizzazione di un 
ensemble di oligomeri eterogenei in cellule vive (circa 6±4 monomeri per 
oligomero) utilizzando un nuovo metodo di microscopia in fluorescenza 
chiamato Number and Brightness analysis. Queste specie oligomeriche inducono 
l’attivazione del sistema autofagico-lisosomiale e la frammentazione dei 
mitocondri in questo modello cellulare. 
Il secondo modello cellulare fornisce un metodo per lo studio delle 
fibrille di alfa-sinucleina e di aggregati più grandi in un ambiente di rilevanza 
fisiologica: alfa-sinucleina è stata sovrespressa in cellule e l’aggregazione è stata 
promossa introducendo nel citoplasma delle cellule frammenti di fibrille ottenute 
da alfa-sinucleina ricombinante, detti seeds. In entrambi i casi la 
sovraespressione e l’aggregazione di alfa-sinucleina hanno causato morte 
cellulare, in buon accordo con quello che è stato riportato in precedenza da altri 
gruppi di ricerca. 
La caratterizzazione dell’aggregazione di alfa-sinucleina in cellule è 
continuata osservando la variazione nel metabolismo cellulare, potenzialmente 
indotta da danni ai mitocondri. Queste variazione sono state quantificate 
misurando le proprietà della fluorescenza del NADH nei due modelli, rispetto al 
controllo. Questi risultati hanno mostrato che in cellule che presentano oligomeri 
o aggregati di alfa-sinucleina, il tempo di vita della fluorescenza del NADH e il 
suo spettro di emissione cambiano. Quindi, queste misure potrebbero essere 
ottimizzare per rilevare la presenza di aggregati di alfa-sinucleina in cellule e in 
vivo, utilizzando un metodo di indagine non invasivo e dye-free. 
La seconda parte della tesi riguarda l’abilità delle proteine chaperoniche 
14-3-3 di interagire con alfa-sinucleina e di interferire con il suo processo di 
aggregazione, riducendone la tossicità in cellule. 
Tra le sette isoforme della famiglia di 14-3-3, la 14-3-3 può revertire il 
processo di fibrillazione di alfa-sinucleina in vitro, portando alla formazione di 
oggetti curvi invece che di fibrille canoniche. Questi oggetti curvi hanno 
diametri e curvature che dipendono dalla quantità di 14-3-3  nel saggio di 
aggregazione: inoltre, molecole di 14-3-3  sono state trovate in questi 
aggregati, suggerendo la formazione di un complesso stabile costituito dalle due 
proteine. Quanto la quantità di alfa-sinucleina è troppo grande o i seeds vengono 
 XI 
 
utilizzati per promuovere il processo di aggregazione in vitro, la 14-3-3  non è 
più in grado di interferire con il processo di aggregazione di alfa-sinucleina e 
viene sequestrata nelle fibrille.  
Nei modelli cellulari, la sovraespressione di 14-3-3  riduce la tossicità 
indotta da alfa-sinucleina quando quest’ultima è soltato sovraespressa e 
oligomerizza, ma non quando l’aggregazione in cellule viene promossa dai 
seeds.  
È stato mostrato, utilizzando tecniche di image correlation spectroscopy 
(cross raster image correlation spectroscopy e cross Number and Brightness 
analysis) che la 14-3-3  sovraespressa può interagire con alfa-sinucleina 
sovraespressa, principalmente alla membrana plasmatica. 
Inoltre, la 14-3-3   viene sequestrata negli aggregati quando il processo 
di aggregazione di alfa-sinucleina è indotto dai seeds, evidenziando un altro 
possibile meccanismo di tossicità dovuto all’aggregazione. 
Tutti i risultati ottenuti in cellule sono in buon accordo con i risultati 
ottenuti in vitro e precedentemente riportati; questo rafforza ulteriormente l’idea 
che le proteine 14-3-3 e in particolare l’isoforma  siano particolarmente 
interessanti nel contesto dello studio dell’aggregazione di alfa-sinucleina e che 
potrebbero essere utilizzare per interferire con il processo di aggregazione e 
ridurne gli effetti tossici. 
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“In the fields of observation chance  
favors only the prepared mind.” 
 
Louis Pasteur 
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1.1 Parkinson’s disease  
1.1.1 Etiopathogenesis and clinical features 
Parkinson’s disease (PD) is the second most common 
neurodegenerative disorder after Alzheimer’s disease and affects about 1% 
of the population over 60 years old (de Lau et al., 2006).  
PD is a motor disorder, characterized by both motor and non-motor 
symptoms. The motor symptoms include resting tremors, usually unilateral 
and in the most distal part of the limbs; rigidity, due to an increased 
resistance in the joints; bradikinesia or akinesia, i.e. slowing down of the 
movements; difficulties in planning, initiating and executing movements; 
postural instability, mainly in the last stages of the disease (Jankovic, 2008). 
Non-motor symptoms are cardiovascular or gastrointestinal symptoms, 
hyposmia and olfactory dysfunctions, anxiety, depression and dementia 
(Dickson et al., 2009). 
Pathologically, PD is characterized by the prevailing death of the 
dopaminergic neurons in the substantia nigra pars compacta (Figure 1.1).  
 
Figure 1.1 – Comparison between the substantia nigra pars compacta in a 
healthy and a PD-affected brain, showing the loss of pigmentation due to 
prominent dopaminergic neurons death. 
 
Functional imaging (i.e. positron emission tomography) suggests 
that about 60% of the dopaminergic neurons in that region have to 
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degenerate and about 80% of dopamine depletion has to occur before the 
first Parkinsonism symptoms display (Dauer and Przedborski, 2003). 
Moreover, proteins and lipids aggregates, termed Lewy Bodies 
(LBs) and Lewy Neurites (LNs), were found in the post-mortem analysis of 
the surviving neurons in brains of patients with a PD diagnosis.  
LBs are eosinophilic cytoplasmic inclusions, whose main 
constituents are ubiquitin and, more important to this thesis, an aggregated 
form of the proteins alpha-synuclein (aS) (Figure 1.2). Electron microscopy 
showed that aS present in LBs and LNs is organized into filaments 200-600 
nm long and with a diameter of 5-10 nm (Spillantini et al., 1998). X-ray 
diffraction revealed that aS filaments in LBs present a -sheet structure 
(Serpell et al., 2000) characteristic of amyloid fibrils. 
 
 
Figure 1.2 – LBs, on the left, and LNs, in the middle, double-stained 
with aS and ubiquitin antibodies (Scale bar 10 m and 90 m 
respectively). On the right, fibrils purified from LBs and immuno-
stained with aS antibody. The gold nanoparticles conjugated with the 
secondary antibody appears as black dots (Scale bar 100 nm). 
Adapted from Spillantini et al., 1998. 
 
Braak and co-workers associated the diffusion of LBs in different 
brain regions to the disease staging (Braak et al., 2003). Pathological studies 
of healthy and PD affected brains have shown that aS inclusions form in a 
similar and precise order in the different regions of diseased brains, 
allowing the identification of six stages of LBs deposition in relationship 
with PD progression (Braak staging is summarized in Figure 1.3). 
Interestingly, aS inclusions can deposit early in the enteric nervous 
system and in the peripheral nervous system (Braak et al., 2006). It is quite 
established now that aS pathology starts in some nerve and spreads in a 
prion-like manner. However, the mechanism(s) by which the pathology 
diffusion occurs is still unclear and several possibilities were proposed in 
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the literature and few will be discussed in section 1.3.3 (Goedert et al., 
2013). 
 
Figure 1.3 – Six stages of PD pathology. Patients with aS deposition belong to one 
of these stages and disease spreading means involvement of additional brain 
regions and symptoms worsening. Stage 1: LBs are observed in the olfactory bulb, 
the anterior olfactory nucleus and/or the dorsal motor nuclei of the vagal and 
glossopharyngeal nerves in brainstem. Stage 2: lesions occur in the pontine 
tegmentum. Stage 3: LBs are found in pedunculopontine nucleus, the cholinergic 
magnocellular nuclei of the basal forebrain, the pars compacta of the substantia 
nigra. Stage 4: the hypothalamus, portions of the thalamus and the anteromedial 
temporal mesocortex (first cortical region). First PD symptoms occur during stage 
3 and early stage 4. Stage 5-6: lesions emerge in the neocortical high-order 
association areas (stage5) and first-order association areas and primary fields 
(stage 6). Adapted from Goedert et al., 2012. 
1.1.2 Etiology of Parkinson’s disease 
PD is mainly sporadic and its etiology remains unclear because it is 
a multifactorial disorder. Several factors can contribute to the disease 
etiopathogenesis: protein aggregation, oxidative stress, genetic 
predisposition, mitochondrial dysfunctions, protein degradation pathways 
failure and exposure to environmental toxins.  
However, about 5-10% of PD cases are genetic and several studies 
identified genetic loci associated to the disease. In particular, mutations in 5 
genes have been identified as strongly related to PD genetic forms. 
Autosomal recessive early onset forms of this disorder are inherited through 
mutations in parkin, DJ-1 or PINK1 genes (Kitada et al., 1998; Bonifati et 
al., 2003; Valente et al., 2004), that encode for proteins involved in the 
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maintenance of mitochondrial function in response to oxidative stress 
(Berman and Hastings, 1999). 
 
Table 1 – Main genes associated to PD. AD = autosomal dominant; AR = autosomal 
recessive. +++, strong; ++, established; + reported in experimental studies; +/- case series. 
Adapted from Tofaris, 2012. 
 
Mutations on Leucine-rich repeat kinase 2 (LRRK2) gene, encoding 
for a large multidomain kinase (Funayama et al., 2002) and on SNCA gene, 
encoding for aS, cause autosomal dominant and late onset forms of PD.  
Other genes were linked to PD genetic forms; they include vacuolar 
protein sorting VPS35 gene, which encodes for a subunit of retromer 
complex, responsible for transmembrane proteins recycling from 
endosomes to the trans-Golgi network and whose mutation causes 
autosomal dominant and late-onset PD (Zimprich et al., 2011); ATP13A2 
that encodes for a lysosomal type 5 P-type ATPase responsible for 
lysosomal acidification (Ramirez et al., 2006; Di Fonzo et al., 2007) and 
causes a parkinsonism with a complex phenotype and dementia.  
Finally, other putative loci and genes have been identified and linked 
to monogenic forms of PD and to susceptibility for the disorder, as for 
example glucocerebrosidase GBA or ubiquitin carboxyterminal hydrolase 1 
Gene 
(locus) 
Inheritance Dementia LBs 
pathology 
Mitochondrial 
regulation 
Lysosomal 
trafficking 
SNCA 
(PARK1-4) 
AD ++ +++ - + 
Parkin 
(PARK2) 
AR - +/- +++ - 
PINK1 
(PARK6) 
AR - +/- +++ - 
DJ-1 
(PARK7) 
AR - ? +++ - 
LRRK2 
(PARK8) 
AD +/- ++ - + 
ATP13A2 
(PARK9) 
AR +++ ? - +++ 
VPS35 (not 
assigned)  
AD +/- ? - ++ 
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UCHL1 (PARK5) gene. For extensive reviews see Hardy 2010, Gasser et 
al., 2011 and Lesage and Brice, 2012. 
1.1.3 SNCA mutations 
SNCA gene was the first gene to be linked to familial PD. In 
particular, single point mutations, i.e. A30P, E46K and A53T 
(Polymeropoulos et al., 1997; Kruger et al. 1998; Zarranz et al. 2004) and 
gene duplication (Chartier-Harlin et al. 2004) and triplication (Singleton et 
al. 2003), were recognized as responsible for autosomal dominant form of 
PD.  
Moreover, the susceptibility to PD is increased when polymorphisms 
are present in some regions of SNCA gene, i.e. in 3’UTR or in the promoter 
region (Fuchs et al. 2008).  
The detailed effects that these mutations have on the protein 
structure and functionality will be discussed further on. These familial PD 
forms establish a further link, after aS fibrils presence in LBs, between this 
protein and this fatal neurodegenerative disorder. 
1.1.4 Clinical treatments 
The therapeutic treatments administrated to patients that are 
diagnosed with PD and show the first symptoms are mainly devoted to the 
restoring of the depleted dopamine or to symptom treatment, because an 
actual cure for this disorder has not been discovered yet. 
The available drugs are dopamine agonists and the precursor of 
dopamine levodopa. These drugs are all able to pass the blood barrier and 
treat the motor symptom of PD, without any effects on the progression on 
the PD pathology (for a review see Shapira, 2009).  
Otherwise a surgical treatment, termed deep brain stimulation (DBS) 
is available. DBS is based on the stimulation of specific brain regions and 
allows the alleviation of PD symptoms rather that curing the disease 
(Krause et al., 2001). 
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A promising therapeutic strategy comes from the application of stem 
cell therapy: grafts from human fetal neuronal tissue in PD patients replaced 
the lost cells and ameliorated the symptoms, proving in principle that this 
treatment is suitable for PD. However, some issues have to be solved: the 
tissue availability, the standardization of the grafts, the collateral effects and 
the fact that the spreading of the disease will hit anyway also the healthy 
grafted neurons, just postponing the problem instead of solving it (Politis et 
al., 2012). 
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1.2 Alpha-synuclein 
The fact that aS is the major component of LBs and LNs and that 
mutations in the gene encoding for the protein lead to autosomal dominant forms 
of PD made this protein a particularly interesting topic for all the people trying 
to unravel PD molecular mechanism(s) and etiopathogenesis. 
aS is a small protein constituted by 140 amino acids that belongs to the 
synucleins family (aS, -synuclein and -synuclein), that share a quite high 
sequence identity and similar expression pattern (Clayton et al., 1998). 
Synucleins are expressed in all the central nervous system, mainly at presynaptic 
terminal in mammalian brains, but their physiological functions are still subject 
of debate.  
1.2.1 Alpha-synuclein structure and function 
aS does not acquire a secondary structure when purified from 
heterologous expression system; for this reason it has always been 
considered a intrinsically disordered protein (Weinreb et al., 1996). 
However, it has been recently purified as an alpha-helical homotetramer 
from mammalian cells overexpressing aS and from human red blood cells 
(Bartels et al., 2011). Other laboratories failed to reproduce the results 
obtained by Bartels and collaborators, and found aS as an unfolded 
monomer in central nervous system, in erythrocytes, in mammalian cells 
and in E. coli (Fauvet et al., 2012). 
The primary structure of aS can be divided in three parts: N-
terminus, non-beta amyloid component (NAC) and C-terminus (Figure 1.4). 
 
 
Figure 1.4 – aS primary structure divided into N-terminus, NAC 
and C-terminus. 
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N-terminus is constituted by the first 60 amino acids and can form, 
along with the NAC region, an amphipatic alpha-helix responsible for aS 
interaction with lipidic membranes (Bartels et al., 2010). The single point 
mutations A30P, E46K and A53T responsible for familial form of PD are 
all located in this region, accounting for variation in protein-membrane 
interaction (see 1.2.2) or in protein aggregation propensity (see 1.2.4). 
The NAC region, from residue 61 to residue 95, is believed to be 
responsible for the primary intramolecular interactions that cause aS 
misfolding and aggregation (Weinreb et al., 1996). This region acquires a -
sheet structure when aS forms amyloid fibrils (see 1.2.4.4).  
The remaining part of the protein constitutes the C-terminus, which 
includes 14 acidic residues and does not acquire a defined secondary 
structure in solution, when aS is bound to the membranes or when it forms 
amyloid fibrils. 
aS physiological function(s) are still not defined, but mounting 
evidences ascribe to the protein a major role in synaptic vesicles recycling 
(Lotharius et al., 2002), in promoting SNARE-complex assembly (Burrè et 
al. 2010) and in neurotransmitters release (Liu et al. 2004). It has been 
shown that aS is involved in synaptic plasticity and learning (Clayton et al., 
1998), even if knockout mice are viable and present only an altered 
dopamine (DA) release and lowered level of striatal DA (Abeliovich et al. 
2000), supporting the hypothesis that aS can be involved in the modulation 
of DA release. 
Furthermore, the fact that aS can be found in both cytosolic fraction 
and bound to the membranes in vivo (Lee et al., 2002) suggests its 
involvement in membrane related function(s), as it will be explain in the 
next paragraph. 
1.2.2 Membrane bound alpha-synuclein 
aS contains an apolipoprotein repeat motif (KTKEGV) in the first 
100 amino acids. For this reason it acquires an alpha-helical secondary 
structure upon binding to detergent micelles, liposomes (Davidson et al., 
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1998) or negatively charged lipids or detergents membranes (Jao et al., 
2004; Jao et al., 2008). Alternatively, aS showed interactions with 
membranes that are composed by a mixture of negative and neutral 
phospholipids (Davidson et al., 1998). 
While C-terminus remains unfolded, it is N-terminus that drives aS 
membrane binding (Bartels et al., 2010) and acquires an alpha-helical 
structure. aS alpha-helix was first described bound to SDS micelles as a 
broken structure, going from residue 3 to residue 92, with a break from 
amino acid 37 to 45 (Ulmer et al., 2005). Other studies supported this result 
(Chandra et al., 2003; Bisaglia et al., 2005), which was further confirmed 
when aS was studied bound to larger lipid vesicles (Bortolus et al., 2008).  
Another model proposed the formation of an extended alpha-helix, 
with a periodicity of 11/3 (Bussel et al., 2005). The idea in this case is that 
the 11 lysine residues lying at the interface between the membrane and the 
protein are responsible for the binding (Jao et al., 2004; Jao et al., 2008). 
The presence of a single extended alpha-helix was also proposed by 
Georgieva and collaborators (Georgieva et al., 2010), but they also 
proposed that both extended and bent helices were possible conformations 
that aS N-terminus can acquire when interacting with detergents and lipids 
(Figure 1.5). 
Other studies suggested that aS can exist in both conformations, 
switching from the extended helix to the broken one depending on the 
binding partners and on the curvature of the membrane (Ferreon et al., 
2009; Trexler and Rhoades, 2009). Moreover, it was also shown that aS 
presents different binding affinities for the membranes depending on the 
diameters of the membrane vesicles used (Middleton and Rhoades, 2010). 
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Figure 1.5 – Membrane bound alpha-helical aS conformational 
changes induced by membranes curvature and lipids concentration. 
Adapted from Ferreon et al., 2009. 
 
Very interestingly, aS binding to the membranes can induce 
membrane curvature and membrane tubulation, as apolipoproteins do 
(Varkey et al., 2010). It has been shown that there is an increased fibrils 
formation when aS is aggregated in the presence of brain membranes (Lee 
et al., 2002) and micelles (Necula et al., 2003), meaning that membranes 
play an important role also in aS aggregation. Moreover, it has been 
proposed that the binding of aS to the membrane increases the local 
concentration, favouring the triggering of the aggregation process (Auluck 
et al., 2010, Lee et al., 2012).  
The increase of aS local concentration at the membranes can lead 
not only to an increased aggregation propensity, but also to membrane 
permeabilization. It has been shown by different groups that monomeric aS 
(Zakharov et al., 2007; Tosatto et al. 2012) and aS oligomers (Kim et al., 
2009; van Rooijen et al., 2010) can form pores with defined conductance 
levels in lipid membranes upon the application of a potential. 
The pathological mutants affect aS membrane binding properties; in 
particular, A30P seems to have a lower ability to interact with lipid 
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membranes in vitro (Perrin et al., 2000; Jo et al., 2002), while E46K 
interacts more easily with negatively charged liposomes, compared to wild 
type aS (Choi et al., 2004). On the contrary, A53T seems to be less affected 
in term of membrane binding variations in comparison to the others (Perrin 
et al., 2000). Accordingly, structural studies suggest that A53T does not 
show any variations when bound to SDS micelles, while A30P induces a 
slight destabilization in the alpha-helical structure close to the site of the 
mutation (Bussell et al., 2004). Similar NMR studies were performed by 
Fredenburg and co-workers (Fredenburg et al., 2007), which lead to the 
conclusion that the modification induced by this mutation does not induce 
relevant alteration of the protein alpha-helical propensity. 
Altogether these indications support the idea of a crucial role for 
membrane bound aS not only in the protein physiological function, but also 
in PD pathogenesis.  
1.2.3 Alpha-synuclein aggregation in vitro 
As previously mentioned, a fibrillar -sheet rich form of aS is the 
major component of LBs and LNs (Spillantini et al., 1998). Considering the 
presence of aS aggregated forms into LBs and the PD-related single point 
mutations that could affect aS stability, functionality and aggregation 
propensity, a significant effort was put over the years into the study of the 
aS aggregation process in vitro. These studies are simplify by the 
availability of recombinant aS, which can be easily expressed in E. coli and 
purified in quite large amount and to a high purity. The interest is related 
not only to aS fibrillization process and aS fibrils, but also to the early aS 
oligomeric intermediates and to those molecules that could interfere with aS 
aggregation. In the next sections a brief presentation of aS aggregation 
kinetics and aS aggregates obtained in vitro can be found. 
1.2.3.1 Aggregation prone alpha-synuclein  
Natively unfolded aS, in pathological conditions, acquires a 
structure prone to aggregate. It is still not clear how this conversion 
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occurs, but considering the importance of this event in the initiation of 
the oligomerization, it has been studied in two different conditions: in 
solution or at the lipidic membranes. 
aS conformational changes were studied in solution by nuclear 
magnetic resonance and molecular dynamics (Dedmon et al., 2004; 
Bertoncini et al., 2005; Allison et al., 2009), and single molecule 
fluorescence techniques (Trexler et al., 2010; Yap et al., 2011).  
All the studies on aS in solution in vitro converged upon the 
identification of long range interactions between C-terminus and the 
central part of the protein and continuous rearrangements of the two 
termini. This means that the unfolded state of aS in solution is 
constituted by an ensemble of different, transient and dynamic 
conformations.  
Some of these conformations can be, in particular conditions, 
prone to establish transient or stable bounds with other aS molecules and 
corresponding to a favorable form. This conformation is an energy 
minimum and drives the first steps of protein oligomerization. 
The increased aS aggregation propensity in the presence of 
membranes (Lee et al., 2002; Necula et al., 2003) could mean that aS 
alpha-helical structure directly converts into a -sheet aggregation prone 
conformation, as it has been shown for other amyloidogenic proteins 
(reviewed in Butterfield and Lashuel, 2010). 
1.2.3.2 Alpha-synuclein aggregation kinetics 
The first steps of self-interaction of aS monomers occur rarely. It 
is primary driven by hydrophobic interactions due to a hydrophobic 
stretch in the middle of aS sequence (from residue 71 to 82), constituted 
by 12 amino acids (VTGVTAVAQKTV) (Giasson et al., 2001).  
After these first steps, monomers start to aggregate and form 
oligomeric species. As soon as their concentration reaches a critical 
point, these oligomers are rapidly converted into protofilaments, 
protofibrils and, finally, into amyloid fibrils (Figure 1.6). 
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Figure 1.6 – Schematic representation of aS aggregation showing the 
different on-pathway aggregation products and the sigmoidal lineshape 
of the kinetic of the process. Adapted from Takahashi and Mihara, 
2008, originally depicting amyloid-beta aggregation process.  
 
Measuring the kinetic of aS amyloid formation, we will observe 
a sigmoidal shape (Figure 1.6): an initial lag phase, that suggested a 
nucleation mechanism, where oligomers acts as nuclei (Wood et al., 
1999); a subsequent fast oligomers assembly into higher molecular 
weight species that lead to a decrease in oligomers concentration and to 
an increase in fibrillar species concentration; eventually, the process 
reaches a plateau, i.e. the chemical equilibrium, when mature fibrils are 
the main polymers in solution. However, the process as described above 
is an oversimplification, since aS aggregation is likely to be more 
complex, characterized by different competing pathways (Kaylor et al., 
2005), leading to multiple forms of aggregation intermediates, 
oligomers and fibrils. 
Several fluorescence spectroscopy techniques allow the 
quantitative determination of the kinetic properties of aS aggregation in 
vitro. Among those, the most commonly used are Thioflavin T (ThT) 
binding assay (Levine, 1993) and fluorescence polarization 
spectroscopy (Luk et al., 2007) (see 2.4.1 and 2.4.2). However, several 
other techniques are available (fluorescence correlation spectroscopy, 
absorbance measurement, dynamic light scattering) and new methods 
are applied to this kind of experiments to overcome some of the current 
limitations (see for example, Nath et al., 2010). 
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These measurements provided information for the comparison of 
the aggregation kinetic in different conditions that lead to the 
identification of the main parameters that have proposed to affect aS 
fibrillization in vitro, i.e. protein concentrations, pH values, buffer 
conditions, temperature and agitation rate and type, solution-air 
interfaces (Giehm et al. 2010). 
Considering the importance of the possible relationship between 
aS pathological mutants aggregation propensity and PD 
etiopathogenesis, several studies have been performed to unravel this 
issue. The kinetic parameters of the pathological mutants fibrillization 
were compared to those of the wild type: A53T presents an increased 
rate of aggregation and a shorter lag phase, while A30P has a longer lag 
phase and a lower growth rate, leading to a decrease in the midpoint of 
the fibrillization transition (Conway et al., 1998; Conway et al., 2000; 
Li et al., 2001). Also the third mutant E46K shows an increased 
fibrillization rate, as A53T does, with a double lag phase compared to 
the wild type (Fredenburg et al., 2007). 
These results show that the effects that missense mutations have 
on aS aggregation propensity is not univocal, raising further questions 
on how mutations affect aS aggregation. 
1.2.3.3 Alpha-synuclein oligomeric species 
In 2004, Pountney and co-workers were able to purify aS annular 
oligomers from inclusions in patients affected by MSA (Pountney et al., 
2004); on-pathway aS oligomeric species were then identified in vitro in 
aggregation assays, but only recently they become more important in PD 
because they were proposed as the most toxic aggregation intermediate 
in the aS fibrillization pathway (Winner et al., 2011).  
Interestingly, Conway and co-workers (Conway et al., 2000) 
observed that both A30P and A53T mutants shared an accelerated 
oligomerization in vitro, but not an accelerated fibrillization, suggesting 
that an increased fibrillization rate is not directly linked to a higher 
cytotoxicity in PD. Accordingly, also E46K mutant, which shows also 
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an increased aggregation rate with respect to wild-type aS, has been 
shown to form soluble non fibrillar species (Fredenburg et al., 2007). 
Given these observations, the characterization of these 
aggregation intermediates acquires more importance, especially if it 
could lead to the identification of putative toxic mechanism(s) related to 
these species (discussed in 1.3.2).  
Unfortunately, the biophysical characterization of aS oligomeric 
species is hindered in vitro by the fact that they often form a 
heterogeneous ensemble, constituted by transient species that are 
difficult to isolate and analyse. Moreover, they seem to be in an unstable 
equilibrium with aS monomers and to convert to aS monomers, 
decreasing their detectable fraction, when size-exclusion 
chromatography is used for their purification (Bhak et al., 2009). 
The fact that size-exclusion chromatography can decrease the 
fraction of detectable could explain the differences in the estimated 
amount of oligomeric species when aS aggregated in solution was 
analysed by size-exclusion chromatography (about 15% of the total 
soluble protein) (Lashuel et al., 2002) or by Small Angle X-ray 
Scattering (SAXS) (about 30-40%) (Giehm et al., 2011 (b)). 
Several groups prepared oligomeric species by mean of different 
protocols (aS aggregation at 37°C, protein incubating on ice or 
resuspension after lyophilisation), testing also the aggregation products 
obtained from the pathological mutants and found a heterogeneous 
ensemble of oligomers (Figure 1.7) (Lashuel et al., 2002; Giehm et al., 
2011 (b); Conway et al., 2000; Kaylor et al., 2005; Fredenburg et al., 
2007).  
These soluble oligomers and protofibrils showed annular or 
elliptical shapes, probed by atomic force microscopy and electron 
microscopy, with diameters going from 4.5 to 55 nm, depending on the 
technique used for the analysis. The estimation of the average number of 
aS monomers constituting these oligomers goes from 16 (Giehm et al., 
2011 (b)) to more than 42 (Conway et al., 2000; Fredenburg et al., 
2007; Lashuel et al., 2002), as well.  
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Figure 1.7 – Oligomeric species analysed by transmission electron microscopy 
(on the left). Scale bar 50 nm. On the right details of the oligomers showing 
different morphologies and the typical annular structure. Adapted from 
Lashuel et al., 2002. 
 
More recently, Cremades and co-workers showed by single 
molecule fluorescence experiments (single molecule two-color 
coincidence detection -smTCCD) that aS oligomeric species are present 
as a heterogeneous ensemble during aS aggregation process. Oligomers 
distribution was divided into three different classes: small (2-5 
monomers), medium (5-15 monomers) and large oligomers (15-150 
monomers) (Cremades et al., 2012), somehow confirming the variety 
reported before. Also the mass fraction of soluble oligomers is in quite 
good agreement with the previous results (less than 5%).  
Oligomers secondary structure was characterized by different 
content of -sheets probed by Raman spectroscopy (Apetri et al., 2006) 
and Fourier transform infrared spectroscopy (Kaylor et al., 2005).    
 As it can be deduced from the various results obtained from the 
biophysical characterization of aS oligomers, several problems arise in 
the study of these species in vitro. The first problem found is the fact 
that oligomers structural, morphological and functional characteristics 
are extremely various and dependent on experimental conditions. The 
second is that varying the technique used for the analysis induces a great 
variability in the obtained results. Finally, the fact that these oligomers, 
mainly obtained in vitro using recombinant aS, are not always found in 
vivo. It is manifest that from the pathological point of view, different 
oligomeric species acquire importance only when evidences that they 
are present in PD cell or animal models or in vivo can be provided. For 
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this reason, the most recent efforts concern mainly their characterization 
in a more physiological environment (see 1.3.2). 
1.2.3.4. Alpha-synuclein amyloid fibrils 
aS amyloid fibrils are the end product of  aS aggregation and the 
most characterized being stable in solution and easy to isolate. They 
share several structural characteristics with amyloid fibrils formed by 
other amyloidogenic proteins (Dobson, 1999) that are linked to other 
neurodegenerative disorders, i.e. Alzheimer’s disease, Huntington’s 
disease, amyotrophic lateral sclerosis (Ross et al., 2005). 
A previously mentioned, the first attempt to study aS fibrils 
structure was performed by X-ray diffraction (Serpell et al., 2000), and 
the data suggested a -sheet structure for the fibrils, with -strands 
perpendicular to the fibril axis. 
 In the early years of 2000, nuclear and electron resonance 
techniques were applied to the characterization of aS fibrils structure: 
the main goal was to define both the structure of the fibril core and of 
the N-term and C-term to finally develop a complete model for aS 
amyloid fibrils. 
The structural features of aS fibrils were studied by site-direct 
spin labeling and electronic paramgnetic resonance (EPR) (Der-
Sarkissian et al., 2003; Chen et al., 2007) and solid state nuclear 
magnetic resonance (ss-NMR) (Heise et al., 2005; Vilar et al., 2008). 
EPR and NMR spectra analysis allowed the determination of the 
fibrils core region, as well of loops, buried sites and secondary structure 
elements. Overall, the data suggest that aS fibrils have a -sheet core 
region (including not only the NAC domain), not exposed to the solvent 
and organized in an ordered in-register parallel structure with -strands 
planes perpendicular to the fibril axis. 5 or 6 -strands, turns and loops 
were identified within this core region, with slight differences for the 
various reports (Figure 1.8). 
The papers propose that N-terminus showed a more 
heterogeneous and less ordered structure, remaining still quite rigid, 
 
 
 
20 Chapter 1 
Introduction   
while C-terminus was describe as flexible and completely unfolded. 
Moreover, Heise et al. and Vilar et al. identified two different types of 
fibrils in the sample (Heise et al, 2005; Vilar et al., 2008).  
In a more recent work (Comellas et al., 2011) Comellas et al., by 
assigning via ss-NMR 106 residues versus 62 residues presented in a 
previous assignment (Heise et al., 2005), further improved the available 
set of data on this topic. The novelty of their model is due to the 
identification of a motif repeated twice in the fibrils secondary structure, 
constituted by a long -strand and two short -strands, which is 
compared in Figure 1.8 (D) with the other results. In Figure 1.9 aS 
molecule is represented, as it should be folded within a fibril, following 
Comellas’ model. 
 
 
 
Figure 1.8 – Core region of aS fibrils: amino acidic sequence and -
strands representation for different models (A) -strands distribution 
obtained from EPR experiments (Chen et al., 2007). (B) -strands in 
two different type of fibrils found aggregating aS and analysing the 
aggregation products by NMR (Heise et al., 2005). (C) Five -strands 
were proposed by Vilar et al., 2008 in a model based on ss-NMR 
experiments. (D) Most recent -strands distribution in aS fibrils core 
regions obtained by ss-NMR assignment (reproposed in an alterantive 
representation in Figure 1.9) (Comellas et al., 2011).   
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Figure 1.9 – Arrangement of aS molecule in fibrils, following the results 
obtained by Comellas et al., (2011) by ss-NMR. Free termini are 
believed to be flexible and responsible for the hierarchical assembly of 
fibrils discussed further on (Figure 1.10, Khurana et al., 2003). Fibril 
axis is perpendicular to the plane that contains the folded protein. 
 
 Comellas and co-workers could also identify structural features in 
N- and C- termini, in disagreement with the previous NMR and EPR 
works. 
aS fibrils morphology was probed by transmission electron 
microscopy (TEM) and atomic force microscopy (AFM). In particular, 
the latter is suitable to study aS fibrils diameters, periodicity and 
curvature, while both can be used to measure fibrils length and to 
qualitatively evaluate their morphology.  
Both these imaging techniques allowed the identification of a 
strong dependence of aS fibrils morphologies, lengths and heights on the 
experimental conditions, i.e. solution pH, salt concentration, aS 
concentration (Hoyer et al., 2002; van Raaij et al., 2008), in good 
agreement with the kinetic and structural data previously discussed. In 
particular, twisted and untwisted fibrils with different periodicity could 
be found. 
More interestingly, van Raaij and co-workers compared the 
morphological characteristics of aS, A30P and E46K fibrils measuring 
heights and periodicities with a robust statistical analysis (van Raaij et 
al., 2006). They found respectively mean heights of 10.0±1.1 nm, 
 
 
 
22 Chapter 1 
Introduction   
8.1±1.2 nm and 9.0±0.8 nm for aS, A30P and E46K fibrils, and 
periodicity of 81±24 nm, 103±20 nm and 76±34 nm.  
Khurana et al. (Khurana et al., 2003) after AFM experiments for 
the characterization of aS fibrils morphology, proposed a hierarchical 
assembly mechanism for the fibrils (Figure 1.10): aS monomers, in 
aggregating conditions, first assembly in protofilaments (3.8±0.6 nm); 
after protofilaments elongation, two of them intertwine and form 
protofibrils (mean height 6.5±0.6 nm), probably to minimize the 
exposure of hydrophobic interfaces. For the same reasons, two 
protofibrils intertwine into mature fibrils (9.8±1.2 nm).  
 
Figure 1.10 – Hierarchical aS fibrils assembly at the latest 
stages. Protofilaments, protofibrils and fibrils diameters 
characterized by AFM (Khurana et al., 2003). 
 
Detailed height measurements for aS fibrils and deletion mutants 
fibrils, lacking N-terminus, C-terminus or both, were performed to 
determine the role of the two terminals in fibril assembly  (Qin et al., 
2007). The authors showed that the removal of C-terminus leads to the 
formation of protofibrils, while in the absence of N-term the fibrils 
structure is conserved, but the mean diameter is smaller because of the 
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N-terminus removal. The absence of both termini leads to the formation 
of protofilaments, further highlighting the key role for C- and N-termini 
in mature fibrils formation.  
1.2.3.5 Aggregation inhibitors and enhancers 
aS fibrillization can be strongly affected by various factors that 
can enhance or inhibit aggregation. It has been shown that fibrils 
elongation rate is directly proportional to protein concentration (Wood 
et al., 1999), which is in good agreement with the fact that SNCA gene 
triplication, responsible for rare and aggressive genetic PD forms, 
causes an increased dosage of aS (Singleton et al., 2003).  
Covalent chemical modifications of aS, such as nitration, 
oxidation and phosphorylation (Serines 87 and 129), lead to variation in 
the rate and in the final products of the aggregation process (Uversky et 
al., 2002; Yamin et al., 2003; Paleologou et al., 2010; Paleologou et al., 
2008).  
Divalent and trivalent metal ions (for example, Al
3+
, Cu
2+
, Fe
3+
 
or Pb
2+
) (Bisaglia et al., 2009) have been shown to strongly accelerate 
aS aggregation rate in vitro. The effect of these compounds suggests a 
critical role for electrostatic interactions in the aggregation rate 
modifications.  
Other molecules, such as chaperones (Dedmon et al., 2005 (b); 
Luk et al., 2008; Ebrahimi-Fakhari et al., 2011) or properly designed 
peptides (El-Agnaf et al., 2004; Sievers et al., 2011), can slow down or 
inhibit aS aggregation process, directly interacting with the protein or 
with other aggregation intermediates. 
The study of a family of molecular chaperones, i.e. 14-3-3 
proteins, that can interfere with aS aggregation process is part of the 
research project presented in this thesis and it will be further discussed 
in this introduction (Section 1.4) and in Chapter 4. 
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1.3 Alpha-synuclein in cell model for PD 
The interest for the study of aS aggregation in cell models is due to the 
idea of correlating specific aS aggregates to potential toxic effects (Section 
1.3.2). This approach seems to be the most promising to find out which are the 
most toxic species in PD, responsible for neurons death, and which are the 
related toxic mechanisms. Moreover, recent findings suggest that misfolded aS 
could be responsible for PD spread in different brain regions, as described by 
Braak staging (see 1.3.3).   
1.3.1 Cell models for the study of alpha-synuclein aggregation  
1.3.1.1 Available cell models and methods  
Two main approaches were used to study aS oligomerization 
and/or aggregation and its toxic effects in cell models. One method is 
based on the transient transfection of aS in cells or on the use of stable 
cell lines overexpressing aS, which can be used to study early steps of 
the aggregation process. However, the overexpression does not lead to 
the formation of large inclusions that resemble LBs; therefore, it can be 
used only to partially study aS aggregation process in cells (Section 
1.3.1.2). To trigger massive aggregation and fibrils formation in cell 
cytoplasm a second method has to be used. Recombinant aS fibrils 
fragments, termed seeds (Wood et al., 1999), are introduced in cells 
during or after aS transfection and lead to the formation of LBs-like 
inclusions (Luk et al., 2009; Danzer et al., 2009; Waxman et al., 2010; 
Nonaka et al., 2010). To validate this cell model several imaging 
experiments were performed days after transfection: cells were fixed 
and immunostained to detect aS and phosphorilated Ser129 aS (Luk et 
al., 2009; Waxman et al., 2010), since the latter has been shown to be 
present in a large fraction of the aS in LBs (Fujiwara et al., 2002). 
 Nonaka et al. performed TEM imaging on cells properly fixed 
and stained (Nonaka et al., 2010). Since TEM microscopy resolution is 
higher than fluorescence confocal microscopy one (about 0.2-2 nm 
versus 200-300 nm), they were able to identify aS amyloid fibrils in cell 
 
 
 
Introduction  25 
 Chapter 1 
cytoplasm, further validating the model. The presence of -sheet forms 
of aS was confirmed also by Thioflavin S measurements (Luk et al., 
2009).  
Besides conventional fluorescence imaging assays, performed on 
cells by staining or immune-staining after fixation, confocal microscopy 
imaging and advanced microscopy techniques, i.e. Förster resonance 
energy transfer (FRET), fluorescence lifetime imaging (FLIM) and fast 
recovery after photo-bleaching (FRAP) were used for a more in depth 
study of aS aggregation in live cells.   
To make aS detectable in live cells, the protein was fused with a 
fluorescent protein or with a tag composed by four cysteines (C4 tag) 
inserted in a 12-mer peptide (FLNCCPGCCMEP). Biarsenical 
compounds (FlAsH and ReAsH) can be used to stain the protein in the 
cytoplasm of live cells: they covalently bind C4 tag and can stain the 
protein directly in the cytoplasm of live cells after permeating cells 
membrane (Roberti et al., 2008). Since the C4 tag plus the biarsenical 
dye have jointly a molecular weight of about 1.3 kDa, it is more likely 
that they cannot seriously affect aS aggregation process. However, some 
drawbacks were shown: FlAsH reagent can bind also to proteins that are 
rich in cysteines, at least in some cell lines, and the staining is typically 
less efficient than the conventional methods of staining (Stroffekova et 
al., 2001; Hearps et al., 2007). 
On the contrary, fluorescent proteins are stable highly specific 
bright molecules, but large and folded (EGFP molecular weight is about 
28 kDa, compared to the 14.6 kDa aS): for this reason they could affect 
aS behaviour and aggregation in cells. In the past years, certain results 
threw doubts about this issue (McLean et al., 2001), but more recent 
data suggest that; aS fused with EGFP or YPF show similar aggregation 
products and kinetics in vitro (van Ham et al., 2010) and are suitable for 
the study of aS aggregation in live cells (Nath et al., 2011). 
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1.3.1.2 Advanced fluorescence microscopy methods  
Biomolecular fluorescence complementation (BiFC) allowed 
Outeiro and co-workers to visualize aS dimers and oligomers in living 
cells (Outeiro et al. 2008 Plos One). The technique is based on the 
generation of BiFC aS mutants, where aS is fused with GFP fragments 
that become fluorescent only when aS molecules associate. The authors 
also demonstrated that these low molecular weight species are essential 
steps for the formation of larger aggregates and are the cause of 
cytotoxicity.  
aS fused with a C4 tag was overexpressed in SH-SY5Y and 
staining was performed with both FlAsh and ReAsH, whose emission 
spectra partially overlap and allowed FRET imaging (Roberti et al., 
2008). Images by confocal microscopy were acquired every 24 hours for 
3 days and FRET analysis was performed. FRET intensity distribution 
defined two different ensembles, one characterized by FRET energies 
between 60% and 80% representing aS aggregates, while the second, 
with energies between 30% and 45%, corresponding to the non-
aggregated form of the protein.  
The same authors further investigated aS aggregation in living 
cells by FRAP and confocal fluorescence anisotropy (CFA) (Roberti et 
al., 2011).  
FRAP data provide information on protein mobile fraction and 
diffusion coefficient D, while CFA evaluates the changes in size of aS 
molecules. In SHSY5Y cells transfected with aS and stained with 
ReAsH, several structures were identified based on the FRAP and CFA 
information:  free protein (D=10 m2/s); membrane bound protein or 
small aggregates and large aggregates.  
FRET measurements were further used to study aS conversion 
into aggregates in cells through the development of a FRET sensor. 
Since aS develops an intrinsic fluorescence emission during the 
aggregation process, Schierle-Kaminski et al. fused aS with a yellow 
fluorescent protein (aS-YFP) and measured FLIM-FRET occurring 
between the growing oligomers and the YFP (Schierle-Kaminski et al., 
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2011). aS-YFP was introduced in SH-SY5Y cells through 
electroporation and measurements of the excited state lifetime allowed 
to monitor FRET pixel by pixel. The average lifetime is about 2970±70 
ps for cytoplasmic homogeneous protein at the beginning of the process 
and becomes 1480±40 ps after 4 days.  
In this thesis other advanced microscopy techniques, described in 
chapter 2, were used to characterize aS oligomerization and aggregation 
in live cells, adding further pieces to the aS aggregation puzzle in live 
cells. 
1.3.2 Alpha-synuclein toxic mechanisms 
Several toxic mechanisms have been related to aS aggregation 
process and aS oligomeric species and fibrils. Given the heterogeneity of 
the aggregation products, it is reasonable to suppose that cytotoxicity can be 
exerted in different ways. 
Among the most studied noxious effects ascribed to aS is the ability 
of monomeric or oligomeric aS of interacting in a disrupting way with lipid 
membranes (Reynolds et al., 2011) or to form well characterized pores that 
are similar to the one formed by the pore-forming toxins and could exert a 
pathological effect (Zakharov et al., 2007; Tosatto et al., 2012; Kim et al., 
2009). Membrane destabilization or disruption and pores formation can 
cause membrane damages, calcium leakage and transmembrane potential 
dissipation (see Butterfield and Lashuel, 2010 for a wide review). 
 To prove if the effects mentioned above are also present in aS cell 
models, aS was overexpressed in dopaminergic doxycycline-treated cells, 
aS aggregates were identified in cells, localized at the cell membranes by 
fluorescence microscopy and conductance variations were revealed (Feng et 
al., 2010). The increased of membrane currents upon voltage application 
was found independently also in HEK293 overexpressing aS (Tsigelny et 
al., 2007).  
If aS oligomers induce plasma membrane destabilization, they could 
also damage intracellular membranes, i.e. vesicles containing 
neurotransmitters (Mosharov et al., 2006) and mitochondrial membranes.  
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The latter are very likely to be damage because of the indirect proof 
of mitochondrial fission and variation in mitochondrial morphology induced 
by aS overexpression in HeLa cells (Nakamura et al., 2011). The authors 
could not verify that the mitochondrial associated aS was in an oligomeric 
form in cells, but were able to demonstrate aS oligomers interaction with 
mitochondrial-like membranes in vitro. Furthermore, aS overexpression in 
PC12 lead to mitochondrial depolarization, mitochondrial-mediated cell 
death (Smith et al., 2005; Tanaka et al., 2001) that could induce ROS 
production. 
However, not only membranes but also other cellular structures are 
affected by the presence of aS or its pathological mutants or its aggregated 
forms. aS overexpression in PC12 cells was shown to induce endoplasmatic 
reticulum (ER) stress (Smith et al., 2005) and Golgi fragmentation was seen 
in COS-7 presenting aS aggregates (Gosavi et al., 2002). The idea of ER 
stress induced by aS was further confirmed by the finding of aS oligomers 
within ER in a in vivo mice model for PD (Colla et al., 2012)  
Both ubiquitin-proteasome system and autophagic lysosomal 
pathway were shown to be involved in the clearance of monomeric, 
oligomeric or aggregated aS. Moreover, clearance mechanisms were 
impaired in some cell and animal models for aS aggregation, probably 
because of the presence of an excessive amount of misfolded protein. The 
literature on these aspects is wide and sometimes controversial: for a 
complete review see Ebrahimi-Fakhari et al., 2012. 
Indirectly, as it was shown for amyloid forming chimeric proteins in 
a recent paper (Olzscha et al., 2012), aS could induce severe disequilibrium 
in proteins homeostasis sequestrating essential proteins during the 
aggregation process in cell. Molecular crowding induced by aS aggregates 
and aS ability of co-aggregating with other proteins or chaperones (Xu et 
al., 2002; Dedmon et al., 2005), as far as the findings, by co-localization 
and proteomics studies, of several proteins in LBs (Shirakashi et al., 2006; 
Xia et al., 2008), further support this hypothesis. 
Finally, it has been shown that neuroinflammation mechanisms 
(reviewed in Maguire-Zeiss and Federoff, 2010) and oxidative stress 
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(Cremades et al., 2012) can be induced by the presence of aS oligomers and 
fibrils.  
Figure 1.11 summarizes the most important toxic mechanisms 
related to aS aggregation in cells. What remains unclear in the PD 
etiopathogenesis is when aS oligomerization or aggregation is the cause of 
the toxicity and when it is the results of previous pathological conditions 
that affect aS normal functionality and induce aS aggregation. 
 
Figure 1.11 – Summary of the main proposed toxic mechanisms related to aS 
aggregation and transmission: membrane damages, mitochondrial dysfunction, 
clearance mechanisms impairment, ER stress and ROS production. Among the 
aS aggregates transmission mechanism (detailed at section 1.3.3): exosome 
transmission, axonal transport and nanotubes transport. 
1.3.3 PD propagation through misfolded alpha-synuclein 
Braak staging for PD states that LBs first appear in the olfactory 
bulb and that only later in the disease evolution LBs emerge in other brain 
regions (Braak et al., 2003). This suggests that the transmission of 
misfolded or aggregated aS from unhealthy to healthy neurons could be 
responsible for the spread of the pathology and the disease progression. 
This hypothesis was further supported on the basis of clinical 
evidences (Kordower et al., 2008; Li et al., 2008), showing the presence of 
LBs in neurons grafted in parkinsonians brains 10 years after surgery. 
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These results drove the first studies in cellular models to verify the 
cell-to-cell transmission of oligomeric aS via endocytosis, which gave 
positive results (Desplats et al., 2009; Hansen et al., 2011). The transmitted 
aggregates work as seeds and trigger aS aggregation process in the recipient 
cells. The same mechanism was exploited in the LBs-like cell models where 
aS seeds were untaken by cells and start inclusions formation (Nonaka et 
al., 2010). 
These first finding lead to more detailed studies on aS aggregates 
transmission among neurons: Volpicelli-Daley and co-workers showed that 
preformed recombinant aS fibrils were uptaken by mice primary cultured 
neurons (Volpicelli-Daley et al., 2011). These fibrils affected neurons 
excitability and connectivity and caused cell death. Moreover, they could 
show that there was intracellular fibrils propagation, due to the movement 
of fibrils from neurons soma to the neurites and vice-versa. In vivo 
preformed fibrils propagation was recently documented by the same group: 
transmission from neuron to neuron in non-transgenic mice brain after 
fibrils injection cause the spreading of PD pathology in mice, which start to 
show the typical PD symptoms (Luk et al., 2012). 
The precise mechanism(s) that cause aS spread from neuron to 
neuron or aS uptake from the extracellular space are not clear and some 
hypotheses have been proposed: (i) direct cell-to-cell transfer due to the 
increased protein concentration in the extracellular space caused by cell 
lysis; (ii) exosomes or vesicles can protect the misfolded protein from the 
proteolitic enzymes and carry it to recipient cells; (iii) molecular chaperones 
can mediate aS transmission; (iv) misfolded aS could move through the 
slow movement of axonal transport; (v) membrane nanotubes 
interconnecting cells over long distances can be an highway for aS 
aggregates (Steiner et al., 2011). 
A couple of hints about the possible mechanism came from two 
recent papers: the first one propose that overexpressed aS can be transmitted 
from transfected SH-SY5Y cells to normal SH-SY5Y cells by exosomes 
(Alvarez-Erviti et al., 2011). The second, showed how fibrillar aS was 
transferd along axons trough anterograde axonal transport, without the 
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requirement of a synaptic contact between soma and axons (Freundt et al., 
2012).  
Among the remaining mechanisms, tunnelling nanotubes, which 
allow the movement of molecules and of cytoplasmic content (Sherer and 
Mothes, 2008) seems promising, given its involvement in prion protein 
transfer (Gousset et al., 2009).  
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1.4 14-3-3 proteins  
The scientific community is showing a growing interest in molecular 
chaperones in the frame of PD studies: indeed, molecular chaperones can assist 
protein folding and modulate protein-degradation pathways (Ebrahimi-Fakhari et 
al., 2011), which are some of the mechanisms impaired in the pathogenesis of 
PD. Moreover, several in vitro studies showed that some molecular chaperones 
or chaperone-like proteins can interfere with aS aggregation process (Dedmon et 
al., 2005; Luk et al., 2008). This evidence could be the basis of the therapeutic 
potential of these proteins, which can prevent protein misfolding and 
aggregation, but the results presented in the literature are not conclusive and 
need to be further consolidated. 
In this frame a family of chaperone-like proteins, 14-3-3 proteins, gained 
relevance in the recent years. 
1.4.1 14-3-3 proteins structure and function 
14-3-3 proteins are a family of highly conserved acidic proteins, 
expressed in the cytoplasm of all eukaryotic cells and represent about 1% of 
the total soluble brain proteins. In humans there are seven 14-3-3 isoforms: 
β/, γ, ε, ζ/, η, σ, and τ, where  and  are the phosphorylated form of β 
and ζ, respectively (Aitken, 2006), associated to a wide range of functions, 
that includes signalling, cell cycle control, apoptosis, exocytosis, 
cytoskeletal rearrangements, transcription and enzyme activity (Berg et al., 
2003). 
 The different 14-3-3 proteins form both hetero-dimers and homo-
dimers (Figure 1.12, panel A), with different propensities depending on the 
isoform, but  and  were found also as monomers (Yang et al., 2006). 
The proteins show a high sequence identity and the X-ray 
crystallographic structure is available for all the isoforms: each monomer in 
a 14-3-3 dimer is constituted by nine antiparallel alpha-helices (termed from 
A to I) (Gardino et al., 2006).  
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Figure 1.12 – 14-3-3 proteins dimerization: hetero- or homo- dimers 
formation (panel A) with the residues involved in the hydrogen bond 
formation highlighted. Secondary structure of 14-3-3 proteins with helices 
and loops properly termed and the groove represented with a circle (Yang et 
al., 2006). 
The first four helices form the dimer interface, while C, E, G 
and I form a peptide-binding groove constituted by a hydrophobic patch 
and a positively charged patch (Figure 1.12, panel B) (Yang et al., 2006). 
The most relevant variation among the different isoforms from the 
structural point of view seems to lie within the loop regions (in particular 
C-D loop) and along the C and D helices (Figure 1.13) (Gardino et al., 
2006). These features may account for the specificity in the interaction with 
their binding partners. 
Actually, 14-3-3 proteins are able to associate with over 100 binding 
partners and, as mentioned before, are involved in the regulation of a wide 
range of cellular processes (Bustos and Inglesios, 2006).  
The main structural feature of 14-3-3 proteins molecular recognition 
is a phosphorylated motif in the binding partners that defines this family of 
proteins as phosphoserine/threonine binding molecules (Yang et al., 2006). 
In addition, there are other reports that identified interactions between 14-3-
3 proteins and the C-terminus of target binding partners (Shikano et al., 
2006). 
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Figure 1.13 – Structure-based sequence alignment of human 14-3-3 proteins 
(Gardino et al., 2006). 
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Different mechanisms of action have been proposed to account for 
14-3-3 ability to modulate so many different cellular processes: (i) 14-3-3 
proteins can induce conformational changes of the target protein; (ii) they 
can physically hinder access to specific structural features; (iii) they work as 
scaffolding protein and (iv) help moving the binding proteins (Bridges and 
Moorhead, 2005).  
 
 
Figure 1.14 – Mechanisms of action of 14-3-3 proteins and related possible function 
(Obsil et al., 2011). 
 
Interestingly, the rationale for the presence of different isoforms in 
14-3-3 protein family is still object of debate: it is still unclear whether they 
have distinct and specialized functions or whether they are just under the 
control of temporal and tissue specific regulation (van Hemert et al., 2004). 
Baxter et al., (2002) reported an isoform-specific characterization of 14-3-3 
proteins distribution in murine brains, providing some hints on the 
importance of the heterogeneous pattern of localization in different brain 
regions. 
1.4.2 14-3-3 chaperone-like proteins and PD 
14-3-3 proteins were shown to be present in the cerebrospinal fluid 
and in some disease-specific lesions and protein inclusions in brains, 
suggesting a possible involvement of these proteins in the pathogenesis of  
neurodegenerative disorders, such a Creutzfeld-Jakob disease, Alzheimer’s 
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disease, polyglutamine diseases, amyotrophic lateral sclerosis, Parkinson’s 
disease and LBs diseases (Berg et al., 2003; Steinacker et al., 2011). 
Interestingly, strong evidence, emerging from clinical and basic studies, 
suggests a role for 14-3-3 proteins also in neurodevelopmental disorders and 
neuropsychiatric disorders (Foote and Zhou, 2012). 
A first potential association of 14-3-3 proteins to PD was suggested 
by the association of a significant portion of 14-3-3 proteins bound to 
synaptic membranes: , , ,  and  are all found in purified synaptic 
membranes, but not to mitochondrial and myelin membranes (Martin et al., 
1994). One of the isoforms (14-3-3 ) was found to activate tyrosine 
hydroxylase, which is the rate limiting factor of dopamine synthesis in 
dopaminergic neurons that are the most affected by PD (Wang et al., 2009) 
Moreover, 14-3-3 proteins were found in LBs in parkinsonian brains 
(Kawamoto et al., 2002; Berg et al., 2003; Umahara et al., 2012). 
But the actual link between this family of chaperone-like proteins 
and PD comes from their ability to interact with a subset of the PD related 
proteins, i.e. LRKK2, parkin and aS.  
LRRK2 is a large multidomain protein member of Roco protein 
family with kinase and GTPase activity. It has been shown that 14-3-3 
proteins have a regulatory effect on its function: LRRK2 pathological 
mutants showed a decreased phosphorylation of two serines, which prevents 
14-3-3 binding and results in subcellular redistribution of LRRK2 and 
neurodegeneration (Dzamko et al., 2010; Nichols et al., 2010). The two 
isoforms most involved in this process seems to be  and  (Li et al., 2011). 
Parkin is an ubiquitine ligase protein that is important for 
degradation pathway that is negatively regulated by 14-3-3  (Sato et al., 
2006).  
More relevantly, to the work that will be presented here, it has been 
shown that 14-3-3 proteins are strongly related to aS, as it will be discussed 
later on (Section 1.4.3).  
Finally, Yacoubian and co-workers observed differential 
neuroprotective effects of the various isoforms of 14-3-3 in dopaminergic 
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cell models for PD where toxicity was induced by MPP+ and rotenone 
(Yacoubian et al., 2010; Slone et al., 2011).  
1.4.3 Alpha-synuclein and 14-3-3 proteins 
The main association between PD and 14-3-3 proteins family 
implies aS protein and aggregation. As mentioned before, 14-3-3 proteins 
were immunohistochemically detected in LBs in human PD: older reports 
suggest that only , ,  and  isoforms are present in the inclusions (Berg et 
al., 2003), while citing preliminary results still not published but anticipated 
in a review Umahara and co-workers propose that all the isoforms are in 
LBs, but the staining can have different intensity (Umahara et al., 2012). 
14-3-3 proteins were also found co-localized with aS in A53T 
transgenic mice, with different distributions in brain regions (Shirakashi et 
al., 2006).  
Ostrerova et al., (1999) found that regions of aS and 14-3-3 shared 
sequence homology: two regions were seen between amino acid 8 and 61 in 
aS that share respectively 43% and 36% of sequence homology with regions 
going from amino acid 45 to 102 in 14-3-3 proteins. This region in 14-3-3 is 
involved in dimerization; therefore, the authors propose that the two 
proteins can interact. Co-immunoprecipitation of aS and 14-3-3 ( and  
isoforms) from rat brain homogenate showed that the two proteins can be 
associated in both cytosolic and membrane fractions. Soluble aS and 14-3-3 
complexes (about 54-83 kDa) were also found in human primary neurons 
cell culture after aS overexpression (Xu et al., 2002). 
Moreover, aS and the isoform  are co-immunoprecipitated from the 
substantia nigra of PD patients (Sato et al., 2006). Interestingly they could 
also show how aS is able to sequester 14-3-3  from parkin-14-3-3  
complex, interfering with the regulation of parkin by the chaperone. Since 
the in vitro interaction between recombinant aS and isoform  could not be 
proved, Sato et al., (2006) suggested that an alternative interaction pathway 
mediated by aS modification could exist. 
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Very interestingly, it was also shown that 14-3-3  and expression 
is upregulated in A53T transgenic mice, while is downregulated and the 
other isoforms expression was unchanged (Kurz et al., 2011). In another 
report ,  and  isoforms were the found to be downregulated in transgenic 
aS mice models (Yacoubian et al., 2010). However, these variations in 14-
3-3 expressions in PD models further link this family of molecular 
chaperons to PD. 
Although the rational for the presence of differential 14-3-3 proteins 
is still not clear, it is plausible that different isoforms could bind different 
ligands mediating the effects described above via independent pathways.  
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1.5 Aim of the project  
The research project proposed in this thesis can be divided into two 
different parts: the first one is releting to the study of aS aggregation in cell 
models, while the second one is related to the study of 14-3-3 proteins effects on 
aS aggregation in vitro and in the same cell models.  
The need of a more detailed characterization of aS aggregation in cells 
is particularly relevant for the first steps of the process: for this reason we 
applied advanced fluorescence microscopy techniques, i.e. Number and 
Brightness method and NADH fluorescence lifetime imaging and spectral 
imaging, to study aS oligomerization and fibrils formation in live cells. 
It is clear from the literature that 14-3-3 proteins can be strongly linked 
to PD and PD related proteins: in particular, 14-3-3  seemed the most 
promising among the 14-3-3 isoforms in term of aS interaction capability.  
The reported interaction in cells and parkinsonian brains between aS and 
14-3-3  does not occur for recombinant proteins, suggesting that a modification 
to the proteins is needed for the binding. The interaction between the two 
proteins was studied during aS aggregation process in vitro and in a cellular 
environment. Moreover, rescue effects due to 14-3-3  overexpression in aS 
aggregation cell models were studied, in order to obtain a deeper understanding 
of the involvement of this chaperone in PD molecular mechanism(s) related to 
aS. 
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“Twenty years from now you will be more 
disappointed by the things that you didn’t do than by 
the ones you did do. So throw off the bowlines. Sail 
away from the safe harbor. Catch the trade winds in 
your sails.”  
 
Mark Twain 
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2.1 Materials 
2.1.1 Growth media  
Luria Bertani (LB): 0.5% w/v yeast extract, 1% w/v Bacto Triptone, 
8.56 mM NaCl, 0.1% NaOH 1N 
LB-agar: 0.5% w/v yeast extract, 1% w/v Bacto Triptone, 8.56 mM 
NaCl, 0.1% NaOH 1N, 1.5% w/v agar 
SOC: 0.5% w/v yeast extract, 2% w/v Bacto Triptone, 8.56 mM 
NaCl, 2.5 mM KCl, 10 mM MgCl2, 20 mM glucose 
HEK293 medium: DMEM (Dulbecco’s Modified Eagle Medium, 
High Glucose, GlutMAZ, Pyurvate - Gibco -), 10% v/v Fetal Bovine 
Serum (FBS – Gibco -), 50 U/ml penicillin, 50 g/ml streptomycin 
SH-SY5Y medium: 50% DMEM (Dulbecco’s Modified Eagle 
Medium, High Glucose, GlutMAZ, Pyurvate - Gibco -), 50% F12 
(Nutrient Mixture F-12 – Gibco -) 10% v/v FBS, 50 U/ml penicillin, 
50 g/ml streptomycin 
2.1.2 Solutions and reagents 
PBS: 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.47 mM 
KH2PO4, pH 7.0 
Osmotic shock buffer: 30 mM Tris, 2 mM EDTA, 40% sucrose 
TBI: rubidium chloride 100 mM, manganese chloride 50 mM, 
potassium acetate 30 mM, calcium chloride 10 mM and glycerol 15% 
v/v, pH 5.8 adjusted with 0.2 M acetic acid, filtered 0.45 m 
TBII: calcium chloride 75 mM, rubidium chloride 10 mM, MOPS 10 
mM, glycerol 15% v/, pH 6.5 adjusted with KOH, filtered 0.45 m    
Stacking gel (4%): acrylamide solution 4%, Tris-HCl 0.125 mM pH 
6.8, SDS 0.1%, APS 0.1%, TEMED 0.1% (acrylamide solution is 
constituted by acrylamide: bis acrylamide ratio equal to 29:1) 
Resolving gel (13%): acrylamide solution 13%, Tris-HCl 0.375 mM 
pH 8.8, SDS 0.1%, APS 0.1%, TEMED 0.008% 
 
 
 
44 Chapter 2 
Materials and Methods   
Running buffer: Tris-HCl 25 mM, glycine192 mM, SDS 0.1%, pH 
8.3 
Coomassie solution: Coomassie Brillant Blue R250 0.25% (w/v), 
ethanol 45 % (v/v), acetic acid 10% (v/v) 
Destaining solution: isopropanol 10% v/v, acetic acid 10% v/v 
Laemmli loading buffer 4X: Tris-HCl 50 mM pH 6.8, SDS 2%, DTT 
100 mM, bromophenol blue 0.1%, glycerol 10% 
Transfer buffer: 25 mM Tris-HCl, 192 mM glycine, 10% v/v 
methanol 
Lysis buffer: 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 
1% v/v Triton X-100, 2.5 mM Na-pyrophosphate, 1 mM -
glycerophosphate, 1 mM NaVO4 
TTBS buffer: 50 mM Tris-HCl, 150 mM NaCl, 0.1% v/v Tween  
2.1.3 Antibodies  
Anti aS: mouse monoclonal antibody, detects aS, epitope maps at aS 
NTD (Syn204, Cell Signaling); WB dilution 1:2000, ICC dilution 
1:100. 
Anti 14-3-3 PAN: rabbit polyclonal antibody, detects all 14-3-3 
isoforms (sc-692, Santa Cruz Biotechnology, Inc.); WB dilution 
1:1000, ICC dilution 1:100 
Anti 14-3-3: rabbit polyclonal antibody against a region between 
amino acids 71-120 of human 14-3-3  (ab28665, ABCAM); 
immuno-TEM dilution 1:100 
Anti 14-3-3: goat polyclonal antibody against a peptide mapping 
near the C-terminus of human 14-3-3(sc-17287, Santa Cruz 
Biotechnology, Inc.); WB dilution 1:200 
Anti β-galactosidase (LacZ): rabbit antibody against the enzyme β-
galactosidase (A11132, Invitrogen); WB diluition 1:1000 
Anti GADPH: mouse monoclonal antibody, detects Glyceraldehyde 
3-phosphate dehydrogenase (GADPH) (MAB374, Millipore); WB 
dilution 1:2000 
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Anti-mouse + HRP: goat antibody conjugated with HRP, detects 
mouse IgG (A4416, Sigma); WB dilution 1:2000 
Anti-rabbit + HRP: goat polyclonal antibody conjugated with HRP, 
detects rabbit IgG (DC03L – Mercl4Bioscience); WB dilution 
1:16000 
Anti-goat + HRP: rabbit polyclonal antibody conjugated with HRP, 
detects goat IgG (A5420, Sigma); WB dilution 1:7500 
Anti-mouse + Alexa Fluor 488: goat antibody conjugated with 
AlexaFluor488, detects mouse IgG (A11029, Invitrogen); ICC 
dilution 1:100 
Anti-rabbit + Alexa Fluor 568: goat antibody conjugated with 
AlexaFluor568, detects rabbit IgG (A11031, Invitrogen); ICC dilution 
1:100  
Anti-rabbit + 10 nm gold nanoparticles: goat antibody conjugated 
with 10 nm gold nanoparticles, detects rabbit IgG (G7402, Sigma); 
immune-TEM dilution 1:30  
2.1.4 Optical microscopes  
Widefield fluorescence microscope: Leica DM 5000B 
Widefield fluorescence inverted microscope: Leica DMI 4000B 
Cofocal microscope: Nikon Eclipse E6000 
(at the Department of Biology, University of Padova, Italy) 
 
Confocal microscope: Olympus FluoView1000 confocal laser 
scanning microscope, using an UPLSAPO 60 × water 1.2 NA 
objective  
Multiphoton confocal microscope: Zeiss 710 confocal laser 
scanning microscope, coupled with a Ti:Sapphire laser (Spectra-
Physics Mai Tai) and an ISS A320 FastFLIM 
(at the Laboratory for Fluorescence Dynamics, University of 
California, Irvine - USA -) 
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2.2 Molecular biology 
2.2.1 Plasmids for protein expression in mammalian cells 
Protein Plasmid Resistance Tag Comments 
14-3-3 
proteins 
pEBG-6P1 Ampicillin 
GST-tag at 
C-terminus 
Gift from Dr. D. 
Alessi (Univ. of 
Dundee, Scotland) 
14-3-3 
pdsRED 
(Clonetech) Ampicillin 
Monomeric 
dsRED at C-
terminus Cloned in the lab 
aS 
pCDNA 
(Invitrogen) Ampicillin - 
Previously 
available in the lab 
aS 
pEGFP-N1 
(Clonetech) Kanamicin 
EGFP tag at 
C-terminus Cloned in the lab 
 
2.2.2 Plasmids for recombinant protein expression 
Protein Plasmid Resistance Tag Comments 
14-3-3/ 
pQE50 
(Qiagen) 
Ampicillin 
His-tag at 
C-terminus 
Gift from Prof. H. 
L. Monaco (Univ. 
of Verona, Italy) 
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14-3-3 
proteins 
pET-28a+ 
(Novagen) Kanamicin - Cloned in the lab 
Wild type 
aS/C141 
mutant 
pET-28a+ 
(Novagen) Kanamicin - 
Previously 
available in the lab 
 
2.2.3 Competent cells 
2.2.3.1 DH5 rubidium chloride competent cells 
A single colony of DH5α E. coli strain was inoculated in 100 ml 
of LB broth. Cells were grown at 37 °C to an OD600nm between 0.22 and 
0.50. Cells were then chilled on ice for 20 minutes and pelleted at 4°C. 
The pellet was resuspended in 20 ml of pre-chilled TBI (see 2.1 
Materials) and kept on ice for 5 minutes. Cells were centrifuged again, 
pellet resuspended in 2 ml of pre-chilled TBII and incubated 15 minutes 
in wet ice. Cells were aliquoted into microcentrifuge tubes, frozen in 
liquid nitrogen and stored at -80°C. 
2.2.3.2 BL21(DE3) calcium chloride competent cells 
A single colony was inoculated in 5 ml LB culture and cells 
were grown overnight at 37°C. The culture was re-inoculated in 100 ml 
of fresh media and grown at 37°C to an OD600nm of 0.3. The culture was 
cooled in ice for 15 minutes. From this point, the protocol has to be 
carried out at 4°C and pre-chill buffers are needed.  
Cells were harvested by centrifugation and pellet resuspended in 
½ of initial volume with calcium chloride 0.1 M (typically 50ml) and 
kept in ice for 30 minutes. Cells were centrifuged again and the pellet 
was resuspended in a calcium chloride 0.1M and 25% glycerol solution 
in 1/50 of the initial volume. The competence starts after 1 hour of ice 
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incubation and increases with time until 24 hours. After 24 hours cells 
are stored at -80°C. 
2.2.4 DH5 and BL21(DE3) cells transformation 
Aliquots of 100 l of competent cells were thawed on ice and 
transformed with about 50 ng of plasmidic DNA. Briefly, after plasmidic 
DNA addition cells were left in ice for 20 minutes and then subjected to 
heat shock at 42°C for 90 seconds.  
Trasformed cells were then grown for 45 minutes at 37°C in SOC 
media. Finally, bacteria were plated on LB-agar petri dishes supplemented 
with the appropriate antibiotic for selection. 
2.2.5 Plasmidic DNA purification  
A single colony of DH5 transformed with the desired plasmid was 
grown overnight at 37°C in an appropriate volume (5 ml for mini-prep or 
200 ml for maxi-prep) of LB media supplemented with 50 g/ml ampicillin 
or 25 g/ml kanamycin. 
Bacteria were then pelleted and plasmidic DNA purification was 
performed using QIAprep Spin Kit (Qiagen) for mini-prep or PureLink 
HiPure Plasmid Filter Maxiprep Kit (Invitrogen), following the 
manufacturer instructions.   
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2.3 Biochemical methods 
2.3.1 Recombinant alpha-synuclein expression and purification 
WT aS and the C141 mutant were expressed in E. coli BL21(DE3) 
strain and grown to an OD600nm of 0.3-0.4 and induced with 0.1 mM IPTG. 
After 5 hours, cells were collected by centrifugation and recombinant 
proteins recovered from the periplasm by osmotic shock using an osmotic 
shock buffer (Huang et al., 2005). Subsequently, the periplasmic 
homogenate was boiled for 15 minutes and the soluble aS-containing 
fraction was subjected to a two-step (35% and 55%) ammonium sulphate 
precipitation. The pellet was resuspended, extensively dialyzed against 
20 mM Tris-HCl pH 8.0, loaded into a 6 ml Resource Q column 
(Amersham Biosciences) and eluted with a 0-500 mM gradient of NaCl. 
Proteins were then dialyzed against water, lyophilized and stored at -20 °C. 
aS purity and integrity after purification was checked by SDS-PAGE 
and reverse phase HPLC chromatography. 
2.3.2 Recombinant 14-3-3 proteins expression and purification 
14-3-3 proteins were expressed in E. coli in BL21(DE3) strains. 
Bacteria were grown at 37°C to an OD600nm of 0.7-0.8, then induced with 
0.5 mM IPTG and grown overnight.  
PMSF 100mM and cocktail of protease inhibitor were added to the 
cells 1:100 (v/v) and cells were subjected to one French Press cycles 
(Constant Systems Ltd). After those, the cell homogenate was centrifugated 
and the supernatant loaded in a Ni
2+
-affinity column and eluted with a 20-
300 mM linear gradient of imidazole in 20 minutes. The elution peak was 
dialyzed against PBS, then incubated overnight at 22°C with thrombin 
protease (according to manufacturer’s instructions, Amersham Biosciences) 
and loaded again in a Ni
2+
-affinity column to separate the protein of interest 
from the cleaved His-tag. The flow-trough was collected, concentrated and 
loaded into a Superdex 200 column (GE Healthcare Life Sciences). The 
eluted protein was stored at 4°C with 3 mM DTT and 0.02% NaN3 as 
 
 
 
50 Chapter 2 
Materials and Methods   
preservative or frozen in liquid nitrogen and stored at -80°C for long-term 
storage. Protein purity, integrity and dimerization were checked after 
purification and/or storage by SDS-PAGE and by size exclusion 
chromatography. 
2.3.3 Recombinant proteins conjugation with fluorescent dyes 
The aforementioned C141 mutant was used to obtain a fluorescently 
labeled aS. Labeling was performed adding a 5-fold molar excess of the 
reducing agent TCEP to C dissolved in 20 mM Tris buffer (pH 7.0). 
After 30 minutes of incubation, Oregon Green 488 maleimide (Molecular 
Probes, Invitrogen) was added to the protein at a 5:1 stoichiometric ratio 
and the reaction was left at 45 °C for 4 hours. The conjugated aS (aS-OG) 
was separated from the unreacted protein, fluorophore, and reducing agent 
by reverse phase HPLC cromatography. 
14-3-3 η was mixed with a 20-fold molar excess of Oregon Green 
488 isothiocyanate F2FITC (Molecular Probe, Invitrogen) in PBS, 20 mM 
Sodium Bicarbonate pH 9.0. The solution containing the conjugated protein 
(14-3-3-OG) was incubated for 5 hour at 25°C and then dialyzed overnight 
against PBS, 5 mM DTT to eliminate the fluorophore excess.  
2.3.4 Protein aggregation assays 
Aggregation experiments were performed at 20 M aS for AFM 
analysis, and at 70 M to follow the kinetic of the process; all aS solutions 
were ultra-filtered with a 100 kDa cut-off Millipore (Sartorius) filter to 
remove possible aggregates from the starting monomeric solution. In some 
of the experiments 14-3-3η was added to afford specific aS:14-3-3 
stoichiometric ratios (please refer to the results section 4.2). For 
fluorescence polarization measurements (Section2.4.1), 1:100 of aS-OG or 
1:25 of 14-3-3η-OG were added. 
The aggregation experiments were carried out in PBS, supplemented 
with 0.05% (w/v) Sodium Azide and 5 mM DTT (when not stated 
differently), at 37°C and providing a constant agitation at 1000 rpm. The 
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sample volume was 200 l and the aggregation was performed on a 96-well 
polycarbonate plates, in PCR vials or in 1.5 ml-volume vials. 
2.3.5 Alpha-synuclein fibrils sonication  
aS fibrils sonication can break fibrils into smaller fibrillar objects 
whose dimensions depends on the sonicator used, on the power and the 
length of the treatment and on the dimensions of the tip. For this reason, we 
believe that a characterization of the objects obtained after the sonication is 
needed, rather than a precise protocol for fibrils sonication that could be 
influenced by the factors above mentioned.    
With this premise, we modulated the sonication protocol used and 
obtained seeds with different characteristics and check them by atomic force 
microscopy. The seeds characteristics are discussed in the Chapters 3 and 4. 
2.3.6 Reverse-phase HPLC chromatography  
Reverse-phase HPLC analyses were performed on aS to verify purity 
and to separate the unbound to the OG-bound aS after protein conjugation 
with the fluorophore.  
The instrument used was 1100 Series HPLC system (Agilent 
Technologies), equipped with a diode array absorbance detector. The 
column connected to the HPLC was Jupiter 5μ C4 300 Å, 150 x 4.60 mm 
(Phenomenex), with a stationary phase constituted by hydrophobic chains 
that interact with the analyte.  
aS was loaded into the column and eluted with a linear gradient of 
acetonitrile (0.085% trifluoroacetic acid) versus water (0.01% trifluoracetic 
acid) in 38 minutes, at a flow rate of 0.6 ml/min. aS’s retention time in this 
conditions is about 18.1 minutes. 
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2.3.7 Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) 
SDS –PAGE allows the separation of proteins according to their size 
in polyacrilamyde gel in the presence of SDS and applying an electric field. 
SDS-PAGE was performed using stacking and resolving gels, prepared as 
described in the Materials section 2.1. 
Before loading protein samples or cell lysates into the gel, samples 
were boiled about 10 minutes in the presence of Laemmli loading buffer. 
Samples were the loaded into the wells and a +100 V potential was applied; 
after the proteins enter the resolving part of the gel, the potential is 
increased to +150 V. The running buffer used was previously described (2.1 
Materials) and the low molecular weight markers were used as reference in 
each gel (Precision Plus Protein dual extra standard, BioRad).  
 After running, gel was stained with Coomassie solution and then 
destained and stored in a 10% acetic acid solution. 
Alternatively, proteins separated by SDS-PAGE were blotted on a 
PVDF membrane (Immobilin-P, Millipore), previously reactivated in 
methanol, applying a 100 V potential for 90 minutes in transfer buffer.    
2.3.8 Western Blot analysis (WB) 
2.3.8.1 Protein quantification for WB 
Before loading cell lysates into SDS-PAGE wells, total soluble 
proteins quantification was performed to allow the loading of the same 
amount of proteins in each different well. Cells were harvested 
mechanically directly in the lysis buffer and kept on ice for 30 minutes. 
The lysates were centrifugated for 30 minutes at 15000 rpm at 4°C and 
supernatants collected. Total protein concentration was assessed via 
Pierce BCA Protein Assay Kit and a plate reader (Victor X3, Perkin 
Elmer). 
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2.3.8.2 Western Blot 
After blotting the proteins on the membrane, it was saturated 
with 10% w/v milk in TTBS (blocking solution) for 30 minutes at room 
temperature. Then the membrane was incubated with the proper primary 
antibody diluted in the blocking solution for 1 hour at room temperature. 
After three TTBS washes, the membrane was probed with the secondary 
antibody diluted in the blocking solution, for 1 hour at room 
temperature. Finally, the membrane, washed three times with TTBS, 
was covered with ECL WB Detection reagents (GE Healthcare) and 
then exposed to an ECL Hyperfilm (GE Healthcare) for a period 
sufficient to detect the bands.  
The film was developed with a developer solution and a fixer 
solution (GBX Kodak). Densitometric bands analysis was performed, 
when needed, using the plug-in of ImageJ properly designed for this 
purpose (http://rsbweb.nih.gov/ij/). 
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2.4 Biophysical methods 
2.4.1 Proteins and DNA quantification 
Proteins absorbance was measured at 280 nm using an UV-visible 
diode-array spectrophotometer (Agilent 8453) and proteins concentration 
was calculated using Lambert-Beer law:  
  
 
  
 
where c is protein molar concentration, A is the measured absorbance at 280 
nm, l is the cuvette light path (usually 1 cm) and  is the protein molar 
extinction coefficient in M
-1
cm
-1 
. 
aS  [M-1cm-1] 
Molecular 
Weight [Da] 
Amino 
acids 
aS WT 5960 14460.1 140 
aS-C141 5960 14563.2 141 
 
The absorbance of aS-OG and 14-3-3η-OG was measured at 496 nm 
with the same spectrophotometer and the concentration was calculated 
considering the molar extinction coefficient of the fluorophore (OG= 81000 
M
-1
cm
-1
) instead the one of the protein. 
14-3-3 isoform  [M-1cm-1] 
Molecular 
Weight [Da] 
Amino acids 
14-3-3  27515 28082.4 246 
14-3-3  29005 29173.9 255 
14-3-3  31985 28302.5 247 
14-3-3  29005 28218.7 246 
14-3-3  27640 27764.2. 245 
14-3-3  27515 27745.1 245 
14-3-3  26025 27774.0 248 
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The molar extinction coefficients  shown in the two previous tables 
are related to all the proteins that were used in this thesis work; they were 
calculated starting from the aminoacidic sequence using ProtParam Tool 
(http://web.expasy.org/protparam/) and are in units M
-1
cm
-1
, at 280 nm in 
water. 
Plasmidic DNA concentration was obtained measuring diluted DNA 
solution absorbance at 260 nm, where it presents its absorbance maximum. 
A 260nm-measured absorbance A of 1 corresponds to a double strand DNA 
concentration of 50 ng/l. Therefore, plasmidic DNA concentration in the 
samples could be easily calculated as follows: 
[ds DNA] = A260 nm · 50 ng/l · diluition factor. 
Plasmidic DNA spectra can give information also on the purity of 
the DNA in term of protein contamination. The ratio between A260nm and 
A280nm should be around 1.8 in a pure double strand DNA preparation. 
2.4.2 Fluorescence polarization 
2.4.2.1 Fluorescence polarization experiments 
Aggregation assays performed on 96-well plates as described in 
section 2.3.4 were monitored with Fluorescence polarization (FP) 
measurements at 535 nm, conducted at intervals of 6-10 hours via a 
plate reader (DTX 880 Multimode Detector, Beckham Coulter). 
Excitation wavelength was 490 nm. 
2.4.2.2 Fluorescence polarization principles 
Fluorescence polarization spectroscopy or anisotropy is a 
suitable tool to study protein aggregation. It was used for the study of aS 
aggregation kinetics in vitro for the first time by Luk and co-workers 
(Luk et al., 2007) and has the big advantage of revealing not only 
protein large aggregates or fibrils but also oligomeric species. 
 The method requires fluorescent molecules in solution; 
therefore, the protein has to be labeled with a fluorescent dye. When 
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excited with a plane polarized light, the protein will emit light in the 
same polarized plane if it remains stationary throughout the excited 
state. On the contrary, the polarization of the emitted light will vary if 
the molecule rotates out of this plane during the excited state. 
Fluorescence polarization P and fluorescence anisotropy r are defined 
as: 
   
      
      
 
   
      
       
 
where I|| is the parallel component of the polarized light, while I⊥ is the 
perpendicular component of the polarized light. 
Both P and r vary depending on the rotational motion of the 
molecules in solution, being a direct relationship between r(t) and 
Stoke’s diffusion law:  
 ( )        
where D is the diffusion coefficient, which is related to the viscosity of 
the solution  and on the dimensions of the objects (d=diameter): 
  
  
     
 
The relationship between r and the diameter of the objects in 
solution allowed monitoring the increasing dimension of aS aggregates 
over time in the presence or absence of 14-3-3. 
2.4.3 Thioflavin T fluorescence assay 
ThT fluorescence emission increases upon binding to -sheets 
structures. Therefore, measuring ThT fluorescence intensity at different 
time points allowed monitoring the quantity of aS fibrils formed over time. 
The assay were performed as described elsewhere (Le Vine, 1993) 
using a microfiltered (cut off 0.22 m) 25 μM ThT solution in 25 mM 
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sodium phosphate (pH 7.0). Constant volume aliquots of protein samples 
were taken at regular intervals during aggregation assays and diluted into 
the ThT-containing buffer (final volume 100 μl). Fluorescence emission 
measurements were conducted on a fluorimeter (Ls50, Perkin Elmer), at 
25°C using an excitation wavelength of 440 nm and recording the ThT 
fluorescence emission spectra between 450 and 600 nm. Emission 
maximum, at 480 nm, was used to quantify the amount of -sheet enriched 
protein. 
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2.5 Cell biology 
2.5.1 Cell culture  
Human Embryonic Kidney 293 cells (HEK293) were chosen 
because they are easy to grow and transfect, while SH-SY5Y neuroblastoma 
cell line was used because SH-SY5Y cells are dopaminergic and considered 
a good model for PD. 
HEK293 and SH-SY5Y cells were cultured in the proper growth 
medium at 37°C in 5% CO2.  
2.5.2 Cell transfection 
pcDNA-aS and pEGFP-aS were used for HEK293 and SH-SY5Y 
transient transfections to obtain suitable models to study aS oligomerization 
and aggregation in fixed and live cells. HEK293 cells were plated between 
50% and 70% confluency, depending on the experiments, and transfected 
using polyethylenimine (PEI) as transfection reagent, with a DNA:PEI ratio 
equal to 1:3 for both the aS expression plasmids used. SH-SY5Y cells were 
plated at about 60% confluency and transfected by Lipofectamine 
(Invitrogen) with a DNA:Lipofectamine ratio ranging from 1:3 to 1:5, 
depending on the experiment.  
pEGFP-aS and pEBG14-3-3 plasmids were used for HEK293 
transient co-transfections, performed in Optimum medium using (PEI) as 
transfection reagent (DNA-PEI ratio was 2:3), when cells were at a density 
of  about 5*10
5
 cells/cm
2
 (about 35% confluency). To assure that almost all 
the cells overexpressing aS-EGFP were also overexpressing 14-3-3, the 
DNA amount ratio was always maintained 2:3. 
HEK293 were also transfected with both pEGFP-aS and pdsRED-
14-3-3 using Lipofectamine as transfection reagent to maximize the co-
expression of the two proteins in advanced imaging experiments. Total 
DNA:Lipofectamine ratio was kept at 1:3.    
When needed, aS seeds obtained as described in Section 2.3.5 and 
characterized as in 4.3, were added to the medium during transfection to 
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induce aS fibrils formation in cell cytoplasm and to obtain LB-like 
inclusions in this cell model. Cells were washed in DPBS (Gibco) and the 
media was changed after 3 hours for Lipofectamine transfected cells and 
after 12-24 hours for PEI transfected cells. 
2.5.3 Immunocytochemistry 
Cells were plated on poly-lysine (50 g/ml solution of poly-L-lysine 
in milliQ H2O) coated coverslips before transfection. At the desired time, 
cells were fixed with methanol at -20°C for 20 minutes, permeabilized with 
PBS with 0.1% Triton and blocked with PBS with 5% FBS (Blocking 
solution). Blocked cells were then stained with the suitable primary 
antibody properly diluted in the blocking solution. The counterstaining was 
done with Alexa Fluor antibodies diluted in blockin solution (see 2.1 
Materials). Cells were also stained with Hoechst 33242 (Invitrogen), diluted 
in PBS or milliQ H2O 1:10000 to visualize the nuclei.  
Widefield images were collected using a fluorescence microscope 
(Leica DM5000B), while higher resolution fluorescence microscopy images 
were acquired with a confocal microscopy (Nikon Eclipse E6000). 
Excitation wavelength for aS-EGFP and Alexa Fluor 488 was 488 nm, 
while for Alexa Fluor 568 it was 568 nm; proper filters were chosen to 
maximize signal and minimize background.  
2.5.4 Organelles staining 
To obtain more information on the effects of aS overexpression and 
aggregation in live cells, staining of mitochondria and lysosomes was 
performed and confocal images were acquired simultaneously with the data 
acquired to perform N&B analysis (Section 2.7.1). 
Lysosome detection was performed staining cells with LysoTracker 
Red (Invitrogen) to a final concentration 100 nM in culture media for 45 
minutes at 37° in 5% CO2. Tetramethylrhodamine ethyl ester perchlorate 
(TMRE) (Sigma) was used to reveal mitochondria. Cells were incubated 
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with TMRE in culture media solution at a final concentration of 500 nM, for 
30 minutes at 37° in 5% CO2. 
Signal from lysosomes or mitochondria, stained respectively with 
LysoTracker and TMRE, were collected on a Olympus FluoView1000 using an 
excitation wavelength of 561 nm, with a laser power from 6% to 12%.  
Filters were set to 505-525 nm for green channel (for N&B signal 
detection) and to 560-660 nm for the red channel (lysosomes or mitochondria). 
Several cells (at least 15) were imaged for each sample in at least 3 independent 
experiments (if not stated differently). 
2.5.5 Time-lapse imaging for cell viability assays 
To perform a viability assay after aS-EGFP overexpression in cells 
in different conditions, HEK293 cells were observed with an inverted 
fluorescence microscope (Leica DMI 4000B) every 12 hours after 
transfection for 3 times, maintaining the same experimental setup in the 
microscope. EGFP or aS-EGFP expressing cells were counted and 
compared to the total cells in the field to measure the viability of 
overexpressing cells over time. To assure significativity to these results at 
least five fields per culture were acquired and the experiments were 
repeated 3 times independently. 
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2.6 Atomic force and electron microscopy 
2.6.1 Atomic force microscopy imaging 
AFM imaging is a very useful tool to characterize aS aggregates: in 
this work it was used to precisely quantify aS fibrils and aggregates 
morphological features, i.e. length, diameters and curvature.  
AFM imaging was performed in tapping mode with Ultrasharp 
NSC15/AlBS silicon probes having a nominal resonant frequency of 325 
kHz (Mikromasch, Tallin, Estonia) on a NanoScope IIIa SFM system 
equipped with a Multimode head and a type-E piezoelectric scanner 
(Bruker, Mannheim, Germany). 10 μl of sample were deposited on freshly 
cleaved mica (RubyRed Mica Sheets, Electron Microscopy Sciences, Fort 
Washington, USA) and left to adsorb for 5 min at room temperature 
(~20 °C). The mica surface was then rinsed with ~500 μl of MilliQ H2O 
(Millipore Simplicity) at the same temperature and dried with dry nitrogen. 
In most experiments, the sample was diluted ~10 times with PBS 
then equilibrated at RT for 10’ prior to deposition in an attempt to minimize 
overlap of individual α-syn aggregates. Multiple images from successive 
depositions were then pooled and digitalized to obtain statistically 
significant morphological measurements as outlined below. AFM imaging 
was performed in collaboration with Dr. M. Brucale, National Research 
Council (CNR), Rome, Italy. 
2.6.2 Electron microscopy imaging 
TEM images are generated by the interaction between the electrons 
beam and the ultrathin specimen that constitutes the samples. TEM can be 
used to study several different kinds of samples, i.e. fixed non-in vivo 
biological samples, and provides a resolution considerably higher than light 
microscopy and that is in the order of nanometers. Electron microscopy was 
used in this work to probe the characteristic of aS aggregates and to verify 
the presence of aS fibrils after inducing the aggregation in cell cytoplasm. 
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TEM samples were prepared by adsorbing a 15 μl aliquot taken 
from an aS aggregation batch onto a carbon-coated copper grid, then 
performing negative staining with a 0.05% uranyl acetate solution.  
For immuno-TEM, grids were first incubated with a rabbit 
polyclonal primary antibody against 14-3-3η (ABCAM) previously 
diluted 1:200 in PBS, then washed in PBS and finally incubated with a 
gold-coupled secondary antibody against rabbit IgG. After a second 
washing step in PBS the grids were negatively stained, as described 
above.  
For electron microscopy, HEK293 or SHSY5Y cells were 
transfected with aS and treated with seeds, cultured for 4 days, fixed 
overnight in 0.1 M sodium cacodylate buffer at pH 7.4 containing 2.5% 
glutaraldehyde; after processing, cells were embedded in LR White resin 
(Polysciences, Warrington, PA). Ultrathin sections were stained with 
uranyl acetate for investigation.  
TEM pictures were taken on a Tecnai G2 12 Twin instrument 
(FEI Company, Hillsboro, OR). 
2.6.3 Automatic fibrils recognition and measuring in AFM and TEM 
images 
Diameters (and curvatures) of the amyloid aggregates were 
measured directly from the AFM images via a semi-automated tool 
(Aioanei, 2012) that automatically recognizes fibrils and interpolates their 
shape with a cubic B-spline function. The Z scale values of the individual 
pixels crossed by the B-spline in the AFM image are pooled to obtain the 
distributions of the apparent diameters. (Local curvature is reported as the 
reciprocal of the osculating circle radius at each pixel crossed by the B-
spline function). 
When recording AFM images to be measured with the fibrils 
recognition tool, special care was taken to obtain images in which the fibrils 
appeared well spread and isolated on the surface rather than overlapped and 
tangled. This analysis was performed in collaboration with Dr. M. Brucale, 
National Research Council (CNR), Rome, Italy.  
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2.7 Advanced fluorescence microscopy 
Considering the limitation of conventional light microscopy techniques 
in the study of complex and dynamic biological system, we decided to go for 
newly developed fluorescence microscopy techniques that were set at the 
Laboratory for Fluorescence Dynamics (LFD), at the University of California, 
Irvine – USA (http://www.lfd.uci.edu/).  
These methods are based on the study of different properties of 
fluorescence signals that are hidden in confocal images (if acquired properly), 
and that are usually not taken into account in conventional confocal microscopy 
assays, i.e. fluorescence intensity fluctuation analysis, fluorescence lifetime 
imaging or spectral imaging. 
The analysis of all these data was performed using SimFCS software, 
developed by Prof. E. Gratton at LFD (http://www.lfd.uci.edu/globals/). 
For all these experiments about 8.5·10
5
 cells were plated in 35 mm 
dishes with a 14 mm microwell for imaging (MatTek, Ashland, MA, USA) 
coated with fibronectin (Invitrogen).  
2.7.1 Number & Brightness and cross-Number & Brightness methods 
2.7.1.1 Number & Brightness and cross-Number & Brightness 
principles 
Number and Brightness (N&B) method is based on fluorescence 
fluctuation analysis and allows separating pixels with many dim 
molecules, from pixels with few bright molecules (Digman et al., 2008 
(a)). The aggregation state of a protein is related to the first (average) 
and second moment (variance) of the fluorescence intensity distribution. 
Considering an average, a small variance corresponds to a large number 
of molecules that contribute to that average, while a large variance 
corresponds to few contributing molecules. The mathematical equations 
that describe the relationship between the average 〈 〉 and the variance 
   of the fluorescence intensity distribution and the apparent number of 
molecules N and the apparent brightness B for every pixel are: 
  〈 〉      
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     〈 〉  
N and B values can be expressed in term of the number of 
particles (n) in the volume of excitation and the molecular brightness : 
    (   )   
       
The N and B values pixel per pixel and their distribution were 
obtained using SimFCS software (www.lfd.uci.edu). One of the 
parameter that has to be calibrated to use the method is the Sfactor, which 
is related to the characteristics of the microscope (Digman et al., 2008 
(a); Ossato et al., 2010). The apparent brightness B of the molecules in 
cells is affected not only by the fluctuation due to fluorescence 
molecules movement, but also by photo bleaching and cell movements. 
To correct for these unwanted contributions a high pass filter algorithm 
(detrend filter) was applied to the stack of images. Detrend filter returns 
the average intensity at each pixel and deletes the fluctuations due to 
motion and photo bleaching that are slower than the particles 
fluctuation. 
The oligomers size S was the calculated considering the B value 
for the monomeric protein and the different brightness values for the 
oligomeric species:  
S = (Boligomers - 1)/ (Bmonomers – 1) 
Considering the average N value we could estimate protein 
concentration in cell cytoplasm. N value calculated by SimFCS is the 
mean apparent number of molecules in the focal volume of the 
microscope. To calculate the real number of molecules the point spread 
function of the microscope has to be considered. The volume of the 
point spread function for a confocal microscope, that is about 0.2 
femtoliter, can be used to calculate the mean concentration of protein in 
cells. 
For a more detailed description of the method and the parameters 
see Digman et al., 2008 (a) and Ossato et al., 2010.  
 
 
 
 
Materials and Methods  65 
Chapter 2 
Cross-N&B method was applied for the study of proteins 
complexes formation in live cells (Digman et al., 2009 (a)). It allows 
detecting the interaction between proteins fused with a fluorescent 
protein; localizing the position of the formed complex and determining 
the stoichiometric ratio between the two proteins in the complex. Cross-
N&B is based on the idea that fluorescence fluctuations corresponding 
to two different fluorescent molecules are correlated only if the two 
interact. Information on the dynamic of the system can be obtained from 
the cross-correlation between the fluctuations of the signals coming 
from the two different fluorescent molecules. 
To obtain these results cross-variance has to be calculated: 
   
  
∑(   〈 〉)(   〈 〉)
 
 
where    ( (or   ) is the intensity of a pixel in the green channel, while 
〈 〉 (or 〈 〉) is the average intensity over the K frames. 
Cross-brightness BCC can be easily derived from    
  just 
normalizing this value with respect to the average intensity for both 
green and red channels (respectively 〈  〉 and 〈  〉): 
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The BCC plot was obtained plotting BCC versus the brightness of 
the two channels B1 and B2, giving as result two different BCC plots. The 
symmetry of these graphs reveals the information concerning the 
presence or the absence of cross-correlation, i.e. interaction. If the plot 
is asymmetric, it means that there is a positive cross-variance and that 
the two molecules interact. On the contrary, when the plot is centered on 
0, it suggests that the fluctuations in the fluorescence are independent, 
as far as the two molecules. 
From this analysis a stoichiometry map can be obtained: this 
contour plot displays the number of pixel in the image that shows each 
possible combination of brightness values in monomer brightness unit. 
This representation allows detecting the most populated region in term 
of a precise B1 and B2 couple, which corresponds to the prevalent 
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complex in that image, with a defined stoichiometric ratio. Detrend filter 
was applied also in this case.  
For a more detailed treatment see Digman et al., 2009 (a). 
2.7.1.2 Number & Brightness and cross-Number & Brightness 
experiments  
For N&B analysis, HEK293 or SH-SY5Y cells were transfected 
with 1 g pEGFP-aS, or pEGF as control, using Lipofectamine 
(Invitrogen) as transfection reagent, with a DNA:Lipofectamine ratio = 
1:5. 
Confocal microscopy data were acquired with the Olympus 
FluoView1000 confocal laser scanning microscope, using an UPLSAPO 
60 × water 1.2 NA objective.  
N&B data were acquired using an excitation wavelength of 488 
nm and laser power was set at 0.1% and 100 frames were acquired for 
each cell, with a pixel dwell time of 20 s. The image size was 256×256 
pixels and the 100 images of each stack were acquired in about 2 
minutes. Imaging started after 24 hours from transfection and cells were 
observed at intervals for 24 hours. 
The laser power and the scanning conditions were calibrated 
transfecting SH-SY5Y and HEK293 with EGFP and measuring the 
brightness value B for the nonaggregating monomeric EGFP. The Sfactor 
obtained for the experiments described in Chapter 3 with this 
instrumentation was 1.32.  
For cross-N&B analysis, HEK293 were transfected with 1 g 
DNA for the single transfection of dsRED, EGFP, aS-EGFP and 14-3-
3-dsRED, or with 2 g total DNA for the co-transfections (aS-EGFP 
and 14-3-3-dsRED, aS-EGFP and dsRED, EGFP and 14-3-3-
dsRED). DNA:Lipoectamine ratio was 1:3. After 24 or 36 hours cells 
were observed using the Zeiss 710 confocal microscope.  
Excitation wavelength for the green channel was 488 nm, while 
for the red channel it was 561 nm, with a laser power of 1% in both 
cases. Internal customized filters were chosen in two wavelength 
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intervals for the two channels, i.e. 490-550 nm for green and 610-661 
nm for red, to avoid overlapping. Pixel dwell time was set at 12.61 s 
and 100 images of 256×256 pixels, with a 50 nm pixel size, were 
acquired in about 1.5 minutes.  
The laser power and the scanning conditions were calibrated 
transfecting HEK293 with EGFP and dsRED independently. The Sfactor 
for each channel were calculated (1.46 for the green channel and 1.25 
for the red one) as far as the brightness B1 and B2. 
2.7.2 Raster image correlation spectroscopy (RICS) analysis and cross-
RICS 
2.7.1.1 RICS and cross-RICS principles 
RICS is a technique used to study protein dynamic on time 
scales going from microseconds to milliseconds in vitro but also in live 
cells. It allows quantifying concentration and diffusion coefficient of 
fluorescent molecules and is based on the idea that the temporal 
information is hidden in the time structure of the scanning method 
(Digman et al., 2005). 
To obtain this kind of information from images, the 2D spatial 
autocorrelation function for each image in a stack acquired by a 
confocal laser scanning microscope is calculated as follows: 
 (   )  
〈  (   )  (       )〉  
〈 (   )〉  〈 (   )〉  
 
where i(x,y) is the intensity of the image at each pixel, and are the 
spatial correlation shifts, i = i - ‹i› and ‹i(x,y)›x,y is the spatial average 
of the image. 
The autocorrelation function is calculated for each image and 
then averaged. The result is fit with the equation that associates the 
correlation with the concentration and the diffusion coefficient of the 
molecules (in the easiest cases). The needed information are 
extrapolated from the fit. 
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For a more detailed protocol and mathematical treatment see 
Rossow et al., 2010. 
 
Cross-RICS method is based on the same idea, but it is applied 
to two different channels (Digman et al., 2009 (b)). Cross-correlation 
function of a raster scan image for two images acquired in both channels 
simultaneously is calculated as follows: 
       (   )  
〈  (   )  (       )〉  
〈  (   )〉〈  (   )〉
 
where I1(x,y) and I2(x,y) are the intensities of the image at each pixel in 
the two different channels and and are the spatial correlation shifts. 
Cross-correlation function in cross-RICS is different from 0 only 
when the fluctuations of the fluorescence in the two channels are 
correlated.  
If the average of the cross-correlation over a stack of images is 
different from 0, it can be concluded that an interaction is occurring 
between molecules in green and red channels. The concentration and the 
diffusion coefficient of the complex can be inferred from the fit of the 
cross-correlation curve (termed cross-RICS map in the results section 
4.8). 
2.7.2.2 Cross-RICS experiments  
For cross-RICS analysis, the same data acquired for cross-N&B 
were used (see 2.7.1.2). 
2.7.3 Fluorescence lifetime imaging and phasor approach 
2.7.3.1 Fluorescence lifetime imaging principles applied to 
autofluorescence in cells and tissues 
Fluorescence lifetime microscopy (FLIM) provides an image 
based on the measurements of time-decay characteristics of a 
fluorescent sample. The fluorescence lifetime of the fluorophores rather 
than the fluorescence intensity is used to reconstruct a FLIM image.  
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Using confocal microscopes or multiphoton microscopes and 
applying this method to the study of cells and tissues can provide useful 
information on the identification and the spatial localization of intrinsic 
fluorescent probes, i.e. flavins, nicotinamide adenine dinucleotide 
(NADH), collagen.  
However, FLIM analysis requires the fitting of the exponential 
decays that characterize fluorescence lifetime. The fits become more 
and more difficult to be done and interpreted with the increased 
complexity of the sample, i.e. cells and tissues, that is why a “fit-free” 
method to analyse FLIM data is needed.  
2.7.3.2 Phasor approach to FLIM 
Digman and collaborators in 2008 suggested that fluorescence 
lifetime data acquired in the time domain could be transformed into 
coordinates in the phasor space (Digman et al., 2008 (b)). 
FLIM data can be analysed by observing the pixel distribution in 
the phasor plot, rather than by fitting multiexponential lifetime decay in 
time domain. 
Tha phasor transformations from time domain to the g and s 
components of the phasor plot are: 
    ( )  
∫     ( )    (  )   
 
 
∫     ( )  
 
 
 
    ( )  
∫     ( )    (  )   
 
 
∫     ( )  
 
 
 
where i and j are the coordinates of a pixel in the image and  the 
frequency (      , with f = laser repetition rate, i.e. 80 MHz in these 
experiments). If the FLIM data are acquired in the frequency domain the 
phasor transformations are:  
    ( )                
    ( )                
Where      and      are the modulation and the phase of the emission 
with respect to the excitation. 
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Lifetime values can be expressed as a function of the modulation 
and the phase:  
   
 
 
    ( ) 
   
 
 
√(
 
  
  ) 
All the possible lifetime decays can be mapped into the spatial 
representation constituted by the phasor plot.  
The coordinates in the phasor plot for a single exponential decay 
 ( )        are: 
 ( )  
 
  (  ) 
 
 ( )  
 
  (  ) 
 
where  is the lifetime of the decay and  is the laser frequency.  
All the single exponential decay lie on the semicircle of radius 
½, going from point (0,0) to point (1,0). Point (1,0) is associated to a 
lifetime of 0, while point (0,0) corresponds to  = ∞. All the 
combination of two single exponential must lie along the line joining the 
two lifetime points that are on the semicircle, while two molecules both 
characterized by a multiexponential decay are identified by two points 
inside the semicircle.  
For a more detailed mathematical treatment and explanation of 
the method see Digman et al. 2008 (b). 
This method was applied to the study of several different 
biological issues, allowing, for example, to determine the different 
metabolic states in germ cells (Stringari et al., 2011) to distinguish 
different stem cells differentiation potential (Stringari et al., 2012) or to 
study milliseconds spatiotemporal dynamics of FRET biosensors (Hinde 
et al., 2013). 
This method allowed us to study aS effects on cell metabolism 
looking at variation in NADH fluorescence lifetime in live cells and in 
vitro. 
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2.7.3.3 Phasor-FLIM experiments  
Recombinant aS was obtained as previously described, 
suspended in sterile PBS pH 7.4 at a concentration of about 250 M. A 
250 μM NADH solution was prepared in PBS pH 7.4.  
NADH solution was measured alone, mixed 1:1 with 1,000 
unit/mL lactate dehydrogenase (LDH; Sigma), mixed 1:1 with the 250 
M aS solution, and after aggregating aS/NADH solution for one or two 
weeks at 37°C under agitation at 1000 rpm. 
For phasor-FLIM analysis, HEK293 were plated as previously 
described and transfected with 2 g of pcDNA-aS (Lipoectamine:DNA 
= 1:2.5) and observed after 36-48 hours . 
Fluorescence lifetime imaging was performed using a Zeiss 710 
coupled with a Ti:Sapphire laser (Spectra-Physics Mai Tai) and an ISS 
A320 FastFLIM. The acquisition settings were:  image size of 256x256 
pixels, pixel dwell time 25 s/pixel and a 63X oil immersion objective. 
A dichroic filter (690 nm) separated the fluorescence signal from the 
laser light and a short-pass filter (610 nm) was placed in front of the 
photomultiplier (H7422P-40, Hamamatsu). The excitation wavelength 
for NADH was 740 nm. 
FLIM calibration was obtained measuring the lifetime of 
fluorescein, which is known to be 4.04 ns. Data were acquired until 
more than 100 counts were collected in the brightest pixel of the image. 
Every pixel in the FLIM image was transformed in a pixel in the 
phasor plot by SimFCS, as previously described. For the analysis of the 
average lifetime in each cell (whole cell or cell cytoplasm), the regions 
of interest in every frame were selected and the average g and s values 
were calculated. 
2.7.4 Spectral imaging and spectral phasor  
2.7.4.1 Spectral phasor principles  
Spectral phasor idea is the same presented for phasor FLIM: the 
analysis and interpretation of spectral data can be complicated in certain 
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conditions. A possible solution is the use of phasor transformation to 
transform the spectral changes occurring at each pixel in a spectral 
image acquired as described below, into a phasor plot. The phasor plot 
shows the spectral properties of each pixel as a function of the 
coordinates of that pixel in a 360° circle.  
This idea was first proposed by Fereidouni and co-workers 
(Fereidouni et al., 2012) and spectral phasor transformations were 
adapted from the equations proposed in a previously published paper 
(Digman et al., 2008 (b)). 
The phasor transformations for the image i and for a discrete 
case were adapted as follows:  
  ( )  
∑  ( )    (   )  
  
    
∑  ( )  
  
    
 
  ( )  
∑  ( )    (   )  
  
    
∑  ( )  
  
    
 
where s and f are the starting and final wavelengths of the spectrum, n 
the harmonic number and  the frequency (      , with f = 
(n·spectral channels)
-1
 ).  
The transformations can be applied to successive harmonic to 
obtain a better distribution of the pixels of the dataset. 
2.7.4.2 Spectral phasor experiments 
Spectral phasor experiments were performed on the very same 
sample solutions prepared for phasor-FLIM experiments (2.7.3.3). 
Data acquisition was done on the Zeiss 710 using a 63×/1.4 Oil 
objective and exciting the sample at 740 nm. The images were acquired 
in the spectral mode of the microscope, using 32 channels with a 9.73 
nm of bandwidth, going from 416.32 nm to 727.65 nm. Pixel dwell time 
was 177 ms, image size was 512×512 and each image was the result of 
an averaging of 2-4 acquisitions. 
Data were acquired using Zeiss software and analysed using 
SimFCS. 
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2.8 Statistical analysis 
2.8.1 Significativity and frequency count 
The statistical analysis for immuno-TEM and on cell images, i.e. 
frequency counts, Student’s test and ANOVA test, were performed using 
OrginPro8 (OriginLab).  
The p value considered statistically significant was p<0.05, 
represented on the histograms with a single “*”. When the p value was 
lower than 0.01, the graphical representation was “**”, while “***” were 
drawn for p<0.001.   
2.8.2 Mitochondria quantitative analysis 
A tailored code (Matlab) for the quantitative analysis of 
mitochondria morphology and distribution in live cells was developed. 
After the selection of a threshold to eliminate the contribution due to the 
background of the TMRE stained mitochondria image, the distances among 
all pixels showing intensity above threshold were calculated to obtain a 
distribution representing the distance between pixels within mitochondria 
and among mitochondria, a parameter that could be associated to 
mitochondrial dimensions and distribution in the cell cytoplasm. 
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In this chapter, results concerning the study of aS oligomerization and 
aggregation in cell models (HEK293 and SH-SY5Y lines) will be presented. aS 
oligomerization in live cells was observed using advanced fluorescence 
microscopy methods (Section 2.7.1 and 2.7.3), while larger aggregates formation 
was studied introducing recombinant aS fibrils fragments (seeds) in cell 
cytoplasm to trigger the aggregation, as it was proposed in the literature. Further 
characterization of the toxic effects induced by aS aggregation was performed. 
Specifically mitochondrial function, autophagic lysosomal pathway activation 
and cell metabolism, through NADH fluorescence imaging, were investigated. 
3.1 Seeding alpha-synuclein aggregation in cells 
The study of aS aggregation in cell models is very important in the 
determination of toxic effect(s) induced by this process. However, there are two 
main issues: (i) limited resolution of conventional microscopy techniques does 
not allow characterizing the early steps of the aggregation process and (ii) simple 
overexpression of aS does not lead to the formation of amyloid fibrils or larger 
LBs-like aggregates, characteristic of PD pathology.  
To overcome the second problem, a new method was recently introduced 
to trigger aS aggregation in cell models (Luk et al., 2009; Danzer et al., 2009; 
Waxman et al., 2010; Nonaka et al., 2010). The method is based on the use of 
fragments of recombinant aS fibrils, termed seeds, that are introduced in cells, 
along with the aS DNA plasmid, through a transfection reagent. aS seeds work 
as nucleation centers in the cytoplasm favoring the formation of aS fibrils 
formed by addition of overexpressed aS. 
The seeds were obtained through sonication of recombinant aS fibrils, as 
described in section (Section 2.3.5), and were characterized by TEM and AFM 
to obtain information on their morphology and on their average dimensions 
(Figure 3.1). Varying the sonication conditions allowed producing seeds with 
different average length and diameters: the characterization of these objects will 
be discussed in a following section, because differences in their dimensions 
affect aS aggregation mainly in vitro (Section 3.2.3), while it is less evident in 
cells. 
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Figure 3.1 - Recombinant aS fibrils fragments, termed seeds, 
obtained as described in the Materials and Methods chapter (Section 
2.3.5). Imaging was done by TEM (on the left) and AFM (on the 
right). 
 
In Figure 3.2, the comparison between cells overexpressing aS and cells 
where aggregation is triggered by seeds are shown in fluorescence microscopy 
images (panel A) and details are shown in a confocal image of a single cell for 
two different samples (panel B). 
 
 
Figure 3.2 – A. Fluorescence microscopy images of cells overexpressing aS, 
on the left, and of cells showing aS aggregates because of aS overexpression 
and seeding (green – aS, DAPI – nuclei). B.  Confocal fluorescence 
microscopy image for the same samples, on the left and on the right, 
highlighting the presence of aS inclusions in cells overexpressing aS and 
treated with seeds. 
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To verify the actual presence of aS fibrils in those cells positive for aS 
immunostaining, we fixed the cells with the methods required for TEM imaging 
that provide higher resolution. It can be clearly observed that cells treated with 
seeds and showing brighter spots in fluorescence microscopy images present 
aggregates, which resemble recombinant aS fibrils (Figure 3.3). 
This method, as reported in the literature, allows obtaining LBs-like 
pathology in cellular models that can lead to a better understanding of the toxic 
mechanism(s) induced by aS pathology (Figure 3.2 and 3.3). We were able to 
obtain aS inclusions in an easy to grow and to transfect cell line, i.e. HEK293, as 
well as in SH-SY5Y cells, which are a dopaminergic line generally considered a 
more suitable as a PD cell model. 
 
 
Figure 3.3 – TEM images of the cytoplasm of untransfected cells (on the 
left) and of the cytoplasm of cells overexpressing aS and treated with seeds 
(on the right), showing aS fibrils. 
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3.2 Cell viability in alpha-synuclein aggregation cell models 
The study of the mechanism(s) of toxicity induced by aS aggregates is 
important for the understanding of the causes of neuronal death in PD. 
Moreover, the availability of validated cellular models for aS aggregation may 
be useful for the identification of molecules that could rescue aS induced 
toxicity.  
To compare, the viability of cells overexpressing aS and cells 
overexpressing aS in which aggregation is triggered by seeds, we performed 
viability assays as described in the Section 2.5.5. The control used to evaluate 
the toxicity induced by the transfection reagents was EGFP overexpressing cells.  
The histograms in Figure 3.4 show the percentage of cells overexpressing 
respectively EGFP, aS-EGFP and aS-EGFP with seeds treatment normalized for 
the control, at 12, 24 and 36 hours after the transfection of HEK293 cells.  
 
Figure 3.4 – Histograms showing the percentage of fluorescence 
cells after 12, 24 and 36 hours from transfection with EGFP, aS-
EGFP and aS-EGFP plus seeds treatment. The percentage of 
fluorescent cells over time accounts for cell viability in the 
different cellular models for aS aggregation, compared to EGFP 
control.  
 
It is clear that while the increase in the percentage of cells overexpressing 
EGFP is constant over time because of the continuous production of EGFP by 
cells that were transfected, the other two samples show a significant decrease in 
the amount of cells showing aS expression.  
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After 12 hours there is no difference between the three populations, but at 
24 and 36 hours after transfection the aS-EGFP overexpressing cells are 
respectively about 65% and 57% of the control. This result indicates that the sole 
overexpression of aS is enough to exert a detectable toxic effect in cells. The 
introduction of aS seeds in cells cytoplasm triggers the aggregation and further 
increases the observed toxicity: at 24 hours the percentage of fluorescent cells is 
about 22% of the control. After 36 hours this value is considerably increased 
(43%) probably because the maximum peak of seeds induced toxicity is around 
24 hours, while later the effect is mitigated by the continuous production of aS 
by the transfected cells that did not uptake seeds during the transfection. Another 
possibility is that part of the seeds starts to be degraded by cellular clearance 
mechanisms (Ebrahimi-Fakhari et al., 2012) at 36 hours from transfection and 
therefore their toxicity is reduced.  
 In the literature it is reported that cell death in aS overexpressing cells 
and aS overexpressing cells plus seeding can be respectively ascribed to 
apoptosis in the first case, because of toxic mechanism(s) induced by aS 
oligomers and to necrosis in the second one, because of damage induced by 
larger aggregates (Nonaka et al., 2010; Nonaka and Hasegawa, 2011).   
In Figure 3.4 it is shown an increase in the percentage of cells 
overexpressing aS-EGFP in the absence or presence of seeds treatment over time 
because of the competition between two mechanisms: the continuous expression 
of the aS by the transfected cells that increases the number of fluorescent cells 
and the concomitant toxic mechanism induced by aS overexpression and aS 
fibrils formation in cells that reduces the fluorescent cells in the sample.  
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3.3 N&B method to study alpha-synuclein oligomerization in live 
cells 
The overexpression of aS and the induction of aggregation by seeding 
produces a cellular model that does allow the study of the latest stages in aS 
aggregation process. To study the early steps in the aggregation process we 
decided to turn to a new method, termed Number & Brightness Analysis, to 
detect possible aS oligomers after aS-EGFP overexpression in HEK293 and SH-
SY5Y. The method is based on the analysis of the fluctuation of the fluorescence 
intensity signal (as described in section 2.7.1) and provides an average value of 
the apparent number of molecules N and the apparent brightness B of a stack of 
fluorescence microscopy images pixel per pixel. N can be directly related to the 
concentration of the protein in cell cytoplasm, while B is associated to the 
average dimension of the molecules in each pixel, i.e. it can be used to determine 
aS-EGFP aggregation state.  
To evaluate the brightness B of monomeric EGFP, we overexpressed 
EGFP in SH-SY5Y cell line and acquire cell images in the conditions described 
in Materials and Methods section 2.7.1.2. After the estimation of the background 
contribution and the background correction, the B value solely due to 
monomeric EGFP in SH-SY5Y was calculated by averaging the B values 
obtained for EGFP in several different cells. In Figure 3.5 (panel A) the B values 
distribution for EGFP in a cell is represented. Fitting each cell histogram with a 
Gaussian curve we obtained a mean value and a standard deviation for B (15 
cells):  
Bmonomer=1.18±0.16 
Figure 3.5 (panel B) reports also the intensity map, the B color map e the 
N color map for a representative cell among those analyzed. B map provides 
information on the distribution of B values in the cells: for EGFP transfected 
cells the B color map shows a homogeneous blue color, representing the average 
value obtained for the monomeric EGFP. The N map on the contrary is more 
heterogeneous, indicating a heterogeneous distribution of the number of EGFP 
molecules in the cytoplasm. The intensity map and the N map are, as expected, 
in good agreement, since the intensity per pixel in this situation is due to the 
monomeric EGFP molecules. 
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Figure 3.5 - A. Gaussian profile of the distribution of the brightness B values of 
EGFP overexpressed in SH-SY5Y cells is centered at B=1.18 and identifies the 
brightness of EGFP monomer under these imaging conditions.  
B. Average intensity image of a cell overexpressing EGFP (Intensity map), B 
map and N map representing respectively the average brightness B and the 
average apparent number of molecules N per pixel. The maps show a 
homogeneous B distribution in the cell cytoplasm, as expected, while the N value 
distribution in the cell varies in good agreement with the Intensity map (color 
scale, a. u). White bar 10 m. 
 
 
After obtaining the B value for monomeric EGFP, which can be 
considered analogous to that of monomeric aS-EGFP, we analyzed the time 
dependence of the fluorescence properties of aS-EGFP transfected cells starting 
from 24 hours after aS-EGFP transfection: aS-EGFP aggregation state was 
evaluated at 24 hours, 36 hours and 48 hours after transfection.  Interestingly, 
even at the first time point the sample presented a detectable level of 
heterogeneity in term of aS aggregation state. 
A class of cells displayed a B distribution centered on approximately 
1.18, which is the B value characteristic of the monomeric EGFP (Figure 3.6, 
panel A). From this result we hypothesized that the protein, at least in the 
conditions described here, is present also as monomer in the cytoplasm. 
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Figure 3.6 - A. Gaussian profile of the distribution of the brightness B of aS-
EGFP overexpressed in SH-SY5Y cells is centered, as expected, at B=1.18 
and identifies the brightness B of aS-EGFP in its monomeric form under 
these imaging conditions.  
B. Average intensity image of a cell overexpressing aS-EGFP (Intensity 
map), B map and N map representing respectively the average brightness B 
and the average apparent number of molecules N per pixel. The maps show 
a homogeneous B distribution in the cell cytoplasm, meaning that aS-EGFP 
is monomeric in these conditions, while the N value distribution in the cell 
varies in good agreement with the Intensity map (color scale, a. u.). White 
bar 5 m. 
 
Next, we examined the conditions of cells 24 hours after the transfection 
and could identify in some cells by N&B analysis, pixels presenting not only a B 
value characteristic of the monomer, but also higher B values, compatible with 
aS oligomeric species. 
Using Bmonomer value as reference, we were able to identify cells 
presenting oligomeric species from the brightness values. As can be seen in 
Figure 3.7 (panel A), the distribution of the brightness B for the representative 
cell transfected with aS-EGFP is broadened, meaning that for some pixels also 
higher B values compared to Bmonomer are calculated. This result indicates that at 
least some of the fluorescence in that pixel can be assigned to aS-EGFP 
oligomers. 
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Figure 3.7 – A. Gaussian profile of the distribution of the brightness B values 
of aS-EGFP overexpressed in SH-SY5Y cells shows a large broadening due 
to the presence of a larger amount of aS-EGFP oligomers. The B value 
distributions for the different oligomeric species cannot be separated from 
the B distribution for monomeric aS-EGFP, however calculating a weighted 
average of the B values accounting for the oligomeric species we obtained 
about 1.95. This overall B value for the oligomers means that they are on 
average constituted by 6 aS-EGFP monomers. 
B. Average intensity image (Intensity map), B map and N map representing 
respectively the average brightness B and the average apparent number of 
molecules N per pixel of a cell overexpressing aS-EGFP, corresponding to 
the Brightness distribution represented in panel B. The maps show a 
heterogeneous B value distribution in the cell cytoplasm, meaning that aS-
EGFP formed oligomers. The N value distribution in the cell varies in good 
agreement with the Intensity map and where the B value is increased, the N 
value is lower than the average (color scale, a. u.). White bar 10 m. 
 
The distribution of brightness values for different cells were very 
different and not well separated from the Gaussian distribution centered on 1.18 
representing the monomeric aS-EGFP. Moreover, it was not possible to separate 
the contribution of oligomers with different dimensions; accordingly, the 
standard deviation of the B values for the oligomeric species is 4-fold larger than 
the standard deviation of the B distribution of monomeric aS-EGFP. With this 
premise, we can only obtain an estimate of the mean brightness of the entire 
heterogeneous ensemble. Considering different cells and different experiments, 
we calculated a weighted average of the brightness of the entire ensemble of 
oligomeric species that is: 
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B = 1.98 ± 0.65 
The equation describing the relationship between the B values measured 
with N&B for a monomer and for oligomeric species and the aggregation size 
allowed us to calculate the mean dimension of the oligomers found in aS-EGFP 
transfected SH-SY5Y. On average, the oligomeric species are constituted by 6±4 
aS monomers, which is in good agreement with a very recent estimate on aS 
early oligomers produced in vitro and observed with single molecules 
fluorescence techniques (n≤10) (Cremades et al., 2012). 
Imaging the cells at different time points after the transfection did not 
influence the percentage of pixels showing oligomeric species that were 
revealed: from about 8% to 30% in different cells. 
We estimated the mean aS concentration in cell cytoplasm for different 
cells overexpressing aS-EGFP. Surprisingly, while the percentage of pixels 
showing oligomeric species in all analyzed cells is significantly variable, the 
mean concentration of aS calculated from the average N value in these cells 
showing oligomers is relatively stable (about 151±38 M). Moreover, looking at 
all the cells, we found a reasonable value for the threshold concentration needed 
for the protein to form oligomers, which is about 80 M.  In those cells where a 
large part of pixels showed the presence of aS oligomers or a very high aS 
concentration, we could not observe a conversion of the oligomeric species into 
fibrillar structure, consistently with what is reported in the literature concerning 
aS aggregation in cell models (Roberti et al., 2007; Klucken et al., 2006) 
These result suggests that both the B value, i.e. the average dimension of 
aS oligomers and the average percentage of pixels in cells presenting oligomers, 
are dependent not only on time, but also on other variables, such as 
concentration or activation of cellular clearance mechanism(s) that target aS 
oligomers.   
Observing more carefully Figure 3.7 (panel B), it is clear that the 
distribution of the pixels containing aS oligomeric species is not homogeneous 
in cell cytoplasm, as if they were constrained in some cellular regions, 
sequestered or bound to cytoplasmic structures, i.e. organelles. 
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3.4 Alpha-synuclein oligomers are sequestered into lysosomes 
and can damage mitochondria 
3.4.1 Alpha-synuclein oligomers sequestration by lysosomes 
To verify if the confinement effect observed for the aS signal while 
looking at the B and the N maps of the cells presenting oligomers could be 
due to the presence of lysosomes sequestration, we stained aS-EGFP 
overexpressing cells and, as control, EGFP overexpressing cells with 
LysoTracker Red. 
From the comparison the B map for aS-EGFP cells with the LysoTracker-
stained lysosomes (Figure 3.8) it is clear that there is a partial overlap, 
suggesting that aS oligomers are enclosed into lysosomes, as shown in a 
mice model by Mak et al., (2010) supporting the activation of ALP when the 
first toxic species form.  
 This result suggests that the presence of aS oligomers lead to the 
activation of the autophagic-lysosomal pathway (ALP) that is believed to be 
responsible for the clearance of misfolded aS (Ebrahimi-Fakhari et al., 
2012). 
It should be mentioned that in lysosomes the pH value is around 5.0. 
This low pH can induce quenching of EGFP fluorescence (Patterson et al., 
1997) and consequentially influence the evaluation of both N and B values. 
However, the control performed on cells transfected with monomeric EGFP 
and stained with LysoTracker does not show any consistent variation in the 
brightness of the monomeric EGFP that colocalizes with lysosomes. 
Therefore, the pH quenching effect may induce (if any) only a negligible 
underestimate of the B values, surely not accounting for the higher 
brightness values assigned to the aS oligomeric species.  
As can be seen in Figure 3.8, not all the pixels presenting oligomeric 
species are enclosed into lysosomes, accounting for a possibly progressive 
activation of the clearance system. 
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Figure 3.8 - Average intensity image (Intensity map), B map and N 
map of a cell overexpressing aS-EGFP and showing localized 
oligomeric species, in comparison with the same cell stained with 
Lysotracker. The correspondence between the pixels showing 
higher B values associated with the presence of oligomeric species 
and pixels positive to Lysotracker staining indicates that at least 
parts of the aS-EGFP oligomers are sequestered into the lysosomes 
after ALP activation (color scale, a. u.). White bar 10 m. 
 
 
3.4.2 Alpha-synuclein oligomers induce mitochondrial fragmentation 
In 2011, Nakamura and co-workers proposed that one possible 
damaging mechanism that could be ascribed to aS is its direct interaction 
with mitochondrial membranes (Nakamura et al., 2011). They showed that 
aS overexpression causes mitochondrial fission, but they could not verify the 
conformation that aS acquired while damaging mitochondria.  
On these premises, the possibility of a direct interaction between aS 
oligomers and mitochondria was explored. To this aim, mitochondria were 
stained with a mitochondrial dye (TMRE) and to verify whether the presence 
of oligomers could be related to the mitochondrial fragmentation as 
previously proposed by Nakamura et al. (Nakamura et al., 2011). 
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The comparison between mitochondria stained with TMRE in cells 
overexpressing EGFP or presenting aS-EGFP oligomers is shown in Figure 
3.9 (Panel A and B). The difference in mitochondrial morphology and 
distribution is clear at glance, but a more precise quantification of these 
variations is also presented (Figure 3.9, panel C). 
 
Figure 3.9 - A. Intensity map of a cell overexpressing EGFP (left panel), as control 
(color scale, a. u.). Corresponding distribution of B values per single pixel versus 
fluorescence intensity for the same cell (center panel), and associated Selection map 
where pixels selected with the red cursor in the B distribution are highlighted in red. 
On the right,  TMRE staining for the same cell. White bar 10 m. 
B. Intensity map of a cell overexpressing aS-EGFP (left panel, color scale, a. u.). 
Corresponding distribution of B values per single pixel versus fluorescence intensity 
for the same cell (center panel), and associated Selection map where pixels selected 
with the red cursor in the B distribution are highlighted in red. The higher B values 
(red pixels in the Selection map) represent the oligomeric species present in this cell. 
On the right, TMRE staining for this cell. White bar 10 m. 
C. Distribution of distances among pixels positive to mitochondrial staining in the two 
cases presented in this figure at point A and B. The blue distribution represents the 
distances between pixels positive to mitochondrial staining in the cells overexpressing 
EGFP, while the black one shows the distances between pixels positive to 
mitochondrial staining in the cell overexpressing aS-EGFP and showing aS-EGFP 
oligomers. Both distributions are normalized by distribution area. The difference 
between the two distributions may account for mitochondrial fragmentation and 
alteration in mitochondria morphology and distribution in the cells cytoplasm of cells 
showing aS-EGFP oligomers, compared to the cells overexpressing EGFP cell. White 
bar 10 m. 
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The distribution of distances between pixels positive to mitochondrial 
staining calculated as described in the Section 2.8.2 were plotted for cells 
overexpressing EGFP and cells overexpressing aS-EGFP and showing aS 
oligomers when analyzed by N&B method. The histograms visualize the 
information about the distribution of the mitochondria in the cell and their 
dimensions: when aS oligomers are present the organelles are smaller and less 
homogenously distributed in the cell cytoplasm, suggesting that they underwent 
to a fragmentation process. TMRE allows not only identifying mitochondria, but 
also to measure their membrane potentials using Nernst equation. In good 
agreement with what was published by Nakamura et al., (2011) we could not 
highlight any difference in the mitochondrial potential based on this experiment. 
 
  
 
 
 
Results. Alpha-synuclein aggregation in PD cell model  91 
Chapter 3 
3.5 NADH FLIM on alpha-synuclein aggregation cell models 
Mitochondrial damages induced by aS overexpression suggested that also 
the NADH cell metabolism could be affected by the presence of aS oligomers 
and/or aggregates (Mayevski and Rogatsky, 2007). In particular, considering the 
higher NADH concentration in mitochondria it is plausible that an alteration in 
NADH fluorescence properties may occur as consequence of mitochondrial 
damages or alterations. 
To test this hypothesis, NADH lifetime was studied in cells in which aS 
oligomers or aggregates were present. aS was overexpressed in HEK293 or aS 
was overexpressed and aggregation was triggered by seeds (aS+seeds) in the 
same cell line and the effects on NADH lifetime variation were analysed in 
comparison with a control (HEK293 cells transfected with the empty vector). 
Considering the overlapping of NADH and EGFP fluorescence spectra, 
we could not use the pEGFP-aS plasmid used in cell viability and N&B 
experiments (sections 3.2 and 3.3) to overexpress aS. Therefore, a pCDNA-aS 
plasmid was chosen, to express wild type aS without any fluorescent tag, while 
seeding was performed as previously described (section 3.1).  
The fit-free method applied to study NADH lifetime, termed phasor 
approach (Digman et al., 2008 (b)), allowed a clear identification of free and 
bound NADH in terms of the differences of their lifetimes, pixel per pixel in the 
autofluorescence images (explained more in detail in section 2.7.3.2). 
The phasor approach to FLIM produces a phasor plot where each pixel of 
a fluorescence image of a cell is represented in a point of coordinates (s,g) that 
corresponds to a precise lifetime of autofluorescence (at least in our case). 
In Figure 3.10 (panel A) the autofluorescence intensities for empty 
vector, aS transfected HEK293 cells and aS transfected HEK293 cells plus 
seeding are shown and compared: it is clear that there are not differences in the 
intensities between the control and the cell models for aS aggregation.   
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Figure 3.10 – A. Two-photon fluorescence intensity signal (color scale, a.u.) for 
HEK293 cells transfected with the empty vector (on the left), with aS (in the 
middle) and with aS plus seeding (on the right). White bar 30 m. 
B. FLIM maps corresponding to the previous reported fluorescence intensity 
signal for each sample, representing the fluorescence lifetime of each pixel in a 
color scale based on the phasor plot (C).  
C. Phasor plot histogram represents the distribution of lifetimes in every pixel 
for 6 images for each sample. Color scale goes from blue, corresponding to the 
lifetime of free NADH, to red, corresponding to bound NADH lifetime. 
 
On the contrary, as it is shown in the FLIM maps and in the 
correspondent Phasor plot (Figure 3.10 panel B and C respectively) there is an 
increase in the lifetime of NADH when aS is simply overexpressed or cells are 
additionally treated with seeds. The FLIM map shows in color scale pixels with 
different lifetimes (the longer in red, the shorter in blue), while the phasor plot 
presents a long tail corresponding to those pixels that have a very long NADH 
lifetime compared to the “normal” free or bound NADH lifetime. These spots 
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with longer lifetime are absent in the control, meaning that this effect is induced 
by aS oligomerization or fibrils formation. However, it is not known if this 
variation in NADH lifetime is due to a direct interaction of NADH molecules 
with aS aggregates or to an indirect effect due to aS aggregates induced toxicity, 
or both. Further experiments were performed to clarify this point (Section 3.6). 
In Figure 3.11, microscopy images of zoomed-in cells in the two 
different aggregation conditions (aS overexpression and aS overexpression plus 
seeding) are presented and the correspondent phasor plot is shown. Here it seems 
that two different components for the pixels showing longer lifetime NADH are 
present (red and green). This result further supports the possibility of multiple 
mechanisms that induce NADH lifetime variation that will be investigated later. 
Interestingly, it seems that the NADH species corresponding to an 
increased lifetime are mainly localized at the cellular membranes. A possible 
explanation for this localization is that this longer lifetime fluorescence is 
coming from NADH trapped into aggregates, which could be localized at the 
membranes, as previously observed by confocal microscopy for LBs-like 
inclusions (Figure 3.2, panel B). 
 
 
Figure 3.11 – A. Zoomed-in fluorescence intensity images of a region of cells 
overexpressing aS and overexpressing aS plus seeding. B. FLIM map 
corresponding to the phasor plot on the right (C), where the pixels selected with the 
green and the red cursors represent two different populations of NADH-bound 
species showing longer lifetimes and localized at the membranes: our interpretation 
suggests that this are the aS aggregates bound to NADH. 
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To quantitatively express the difference in the NADH lifetime between 
the three different samples, we calculated for every cell the average of the 
coordinates g and s of the phasor plot related to each pixel, which correspond to 
a specific lifetime, considering the whole cell or only the cell cytoplasm. Then 
we plotted g and s for cells overexpressing aS and for the control (Figure 3.12) 
for the whole cell or for the cell cytoplasm.  
 
Figure 3.12 - Scatter plot of the phasor FLIM signature of each cell of a 
sample transfected with the empty vector and the other with aS. Each point 
represents the average phasor value in an individual cell of the two samples, 
being g and s the coordinates of each pixel in the phasor plot. In the first 
graph the average phasor value is calculated for the whole cell and in the 
second only for the cell cytoplasm. 
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In both cases, it is clear that two different populations in term of lifetimes 
are present, corresponding to aS overexpressing cells compared to the control. 
The non-complete separation is likely due to the contribution of those cells that 
are in the aS transfected cell ensemble, but that are not really transfected because 
of the transfection efficiency, which is about 30% for HEK293 transfected with 
pCDNA-aS.  
The separation between the two populations is more evident when the 
mean lifetime is calculated only for the pixels placed in the cell cytoplasm, not 
for the whole cell. The NADH fluorescence signal in the cytoplasm comes 
mainly from mitochondrial NADH; therefore, the fact that variations in NADH 
are more evident in the cytoplasm suggests that the effects we are looking at may 
involve mitochondria and/or bound NADH. 
Figure 3.13 shows the scatter plots for g and s values of aS 
overexpressing cells treated with seeds, compared to the control. In this second 
case the two populations are not clearly separated: this result can lead to few 
considerations. One explanation is that seeds lead to the formation of larger 
aggregates in cells, but they encompass a lower number of pixels compared to 
the oligomers, which are smaller, but in greater number. A second possible 
explanation is that seeds exacerbate a toxic situation that is present when aS is 
overexpressed, increasing toxicity as it was shown before (Section 3.2) and the 
consequent cell death in cells overexpressing aS; for this reason there is a 
reduction of the cells showing a longer NADH lifetime. 
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 Figure 3.13 - Scatter plot of the phasor FLIM signature of each cell of 
a sample transfected with the empty vector and the other with aS and 
treated with seeds. Each point represents the average phasor value in an 
individual cell of the two samples, being g and s the coordinates of each pixel 
in the phasor plot. In the first graph the average phasor value is calculated 
for the whole cell and in the second only for the cell cytoplasm. 
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3.6 Lifetime and spectral characterization of NADH and alpha-
synuclein aggregates in vitro 
There are some different possible explanations for the longer 
autofluorescence lifetime induced by aS overexpression: (i) aS overexpression 
causes the variation of NADH lifetime in an indirect way, acting on other 
proteins or pathways; (ii) longer autofluorescence could be due to other 
autofluorescence sources in the cell (i.e. flavins, lipofuscins); (iii) aS 
oligomerization causes the sequestration of NADH by aS oligomers or larger 
aggregates, leading to an increase of NADH fluorescence lifetime that was also 
demonstrated for other NADH-oligomeric proteins complexes (Jameson et al., 
1989). 
To rule out the second possibility, concerning other contributes to the 
detected fluorescence signal, we changed the excitation wavelength exploring 
other regions of the spectrum. This experiment allowed seeing if the contribution 
to the variation in autofluorescence lifetime was not due to NADH only, but to 
other autofluorescence sources whose excitation maximum corresponds to other 
wavelengths.  
 
Figure 3.14 – Selected cell overexpressing aS and imaged in transmission 
and exciting at different wavelengths to verify the absence of contributes 
due to other sources of autofluorescence, i.e. flavins, lipofuscin. 
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As can be observed in Figure 3.14, exciting cell samples with different 
wavelength (720, 740, 760, 800 and 850 nm) does not show any increase in 
fluorescence signal, excluding the possibility of a strong contribution due to 
flavins or lipofuscins.  
3.6.1 In vitro characterization of NADH lifetime variation in the 
presence of monomeric or aggregating alpha-synuclein 
Considering the results shown in the previous paragraph, lifetime 
variations are mainly ascribable to NADH lifetime variation. To test if the 
longer lifetime was due to a direct interaction between NADH and aS, we 
performed some in vitro assays. NADH alone, NADH and aS, NADH and 
lactate dehydrogenase (LADH) and, finally, aS aggregated for one or two 
weeks in the presence of NADH were imaged, in the experimental 
conditions described at section 2.7.3.3. 
FLIM analysis was performed for the different samples and the 
results are summarized in figure 3.15. NADH lifetime (red cursor in the 
image) and LADH-NADH lifetime (green cursor) are positioned in the 
phasor plot as expected and previously published (Stringari et al., 2011) 
(Figure 3.15, panel A).  
Surprisingly, also monomeric aS (pink cursor) induces a variation in 
NADH lifetime that is different from the one induced by aS aggregation 
(blue cursors) (Figure 3.15, panel B). To explain this variation we suggest 
that NADH could be sequestered into aS oligomeric species and amyloid 
fibrils, changing its fluorescence properties. 
In both panel A and B, NADH lifetime distribution after its 
aggregation with recombinant aS is shown (blue cursor). In panel A, a two-
week aggregation is shown, while in panel B indicates one-week 
aggregation. This difference could partially account for the distance 
between the two distributions in the phasor plot. 
However, other aspects should be considered: (i) variation in the 
observed field that can lead to different amount of detected aggregates 
contributing to the signal; (ii) the heterogeneous distribution of aggregates 
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in solution that probably induce different variation in NADH fluorescence 
lifetime. 
 
Figure 3.15 – A. In this phasor plot the position of the lifetimes corresponding 
to different NADH containing solution is represented: free-NADH and NADH 
bound to LADH as references, and aS aggregated in the presence of NADH for 
two weeks.  
B. In this phasor plot the position of the lifetimes corresponding to other 
NADH containing solution is represented: free-NADH as reference, aS and 
NADH containing solution, and aS aggregated in the presence of NADH for 
one week. 
C. In this panel, the NADH fluorescence intensity (color scale, a. u.) of aS 
aggregated in the presence of NADH solution is shown (on the left). The 
corresponding phasor plot is represented in the middle: it shows a broaden 
distribution accounting for species with different lifetimes, probably aS 
oligomers or aggregates that sequester NADH and change its fluorescence 
properties. In the selection map, on the right, the red pixels selected with the 
red cursor in the phasor plot represent the free NADH, while the blue pixels 
correspond to the large and bright object in the intensity map and show longer 
lifetimes.  
 
Zooming in to further magnify the aggregates (Panel C) shows how 
the NADH containing species in solution present different lifetimes, going 
from the value corresponding to free NADH to the one that in panel B was 
assigned to aS fibrils. Using the blue cursor we highlighted the longer 
NADH lifetime objects, which correspond, in the intensity image on the 
right, to large brighter spots that we propose are aS fibrils.  
 
 
 
100 Chapter 3 
Results. Alpha-synuclein aggregation in PD cell model   
NADH-aS aggregates morphology was assessed by AFM and their 
morphology resemble perfectly the one of canonical fibrils obtain 
aggregating aS alone; the results are shown in Figure 3.16. 
 
Figure 3.16 – AFM micrograph of aS fibrils obtained aggregating 
the recombinant protein with NADH for two weeks. 
 
3.6.2 Spectral characterization of NADH fluorescence in the presence of 
monomeric or aggregating alpha-synuclein 
To further characterize the differences in NADH properties in the 
presence of monomeric aS or when the protein is aggregates with NADH, 
we performed spectral phasor analysis on this sample. 
Figure 3.17 reports the spectral phasor plot for free NADH (panel A) 
and for NADH in solution with aS (panel B). The position of the 
distribution in the spectral phasor plot allows the determination of the 
maximum of the spectra corresponding to each samples and the width of the 
Gaussian, assuming that the spectra could be fitted with that curve. For free 
NADH  = 480.5 nm and Gaussian width is 46.2 nm, while for NADH in 
the presence of monomeric aS =481.5 nm with a width of 43.4 nm.  
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Figure 3.17 – Spectral phasor plot of NADH in solution (panel A) and 
to aS and NADH in solution (panel B), and correspondent 
fluorescence intensity. The 360° angle corresponds to the spectral 
range observed (from 416.32 nm to 727.65 nm) and the position of the 
pixels distribution in the spectral phasor plot corresponds to the 
maximum of the fluorescence spectra in each conditions when fit with 
a Gaussian profile. 
 
In figure 3.18 is reported the same kind of analysis for the sample 
containing aS aggregated with NADH. In panel A the spectral phasor plots 
corresponds to all the pixels that constitute the image, while in panel B an 
intensity threshold was set to eliminate the pixels presenting lower signals. 
Using this method all the contributions due to free NADH that was still in 
solution with aS aggregates were eliminated and the distribution in the 
spectral phasor plot was sharper. This analysis allowed calculating the 
spectra maximum for NADH molecules that co-aggregated with aS: 
=476.6 with width 47.5 nm.  
 
 
 
 
102 Chapter 3 
Results. Alpha-synuclein aggregation in PD cell model   
 
Figure 3.18 – Spectral phasor plot of NADH aggregated with aS for one week and 
correspondent fluorescence intensity (panel A). The 360° angle corresponds to the 
spectral range observed (from 416.32 nm to 727.65 nm) and the position of the pixels 
distribution in the spectral phasor plot corresponds to the maximum of the 
fluorescence spectra in each conditions when fit with a Gaussian profile. To obtain a 
less noisy pixel distribution in the spectral phasor a threshold was selected to 
eliminate the contribution due to free NADH. Spectral phasor of NADH aggregated 
with aS with a threshold (panel B), correspondent intensity and selection map (red 
cursor in the spectral phasor and red pixels in the selection map). 
 
The shift of the spectra maximum toward smaller wavelengths 
compared to the free NADH is in good agreement with what is reported in 
the literature on the spectral variation of NADH bound to other proteins 
(Table 3.1). 
 
 Free 
NADH 
NADH-
aS 
NADH-aS 
aggregation 
Free 
NADH* 
Bound 
NADH* 
Flavins* 
 (nm) 480.5 481.5 476.6 459 448 528 
FWHM 
(nm) 
46.2 43.4 47.5 91 91 77 
Table 3.1- Summarizing table for NADH spectrum maximum obtained by spectral 
phasor analysis for free NADH, NADH-aS solution and aS aggregated in the presence 
of NADH, and reported in the literature (Palero et al., 2011) for free NADH, bound 
NADH and flavins. 
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This consistent variation in term of spectral properties of NADH 
autofluorescence further supports the idea that NADH is bound to aS 
aggregates or fibrils and this binding strongly affects its fluorescence 
properties. 
It is clear that monomeric aS, aS oligomerization and aS aggregation 
cause an increase in NADH fluorescence lifetime, compatible with the 
results that we obtained in aS cell models, and a shift in the maximum of 
fluorescence emission spectra in vitro.  
This suggests that NADH autofluorescence properties could be used 
as label-free biomarker to observe aS aggregation progression in vitro, but 
also in cells and animal models. 
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3.7 Conclusions 
These results show the characterization of aS aggregation in two different 
cells models. One allowed the characterization of aS oligomerization in live cells 
using confocal fluorescence fluctuation measurement and N&B analysis. These 
aS oligomers seem to be responsible for cellular toxicity and mitochondrial 
fragmentation. Moreover, they were found enclosed into lysosomes, suggesting 
the activation of ALP for oligomers clearance. 
The other model here presented is devoted to the study of larger aS 
aggregates that resemble LBs and are obtained in cells triggering the aggregation 
with seeds.  
In both cases a cell viability assay showed that aS oligomerization and 
aggregation induce cell death. 
Considering the mitochondrial damage exerted by aS oligomers, the idea 
of an impairment of the cellular metabolism arose. To test this possibility, 
NADH fluorescence properties were characterized in the two cell models 
proposed for the study of aS aggregation and for aS aggregation in vitro, as 
control. 
Interestingly, it has been shown that aS aggregation induces variations in 
NADH fluorescence lifetime and NADH spectral properties, suggesting that it 
could be used as a dye-free reporter for the study of aS aggregation in vitro, in 
cells and in vivo. 
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“Imagination is more important than knowledge. 
For knowledge is limited, whereas imagination 
embraces the entire world, stimulating progress, 
giving birth to evolution. It is, strictly speaking, a 
real factor in scientific research.” 
 
Albert Einstein 
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14-3-3 proteins effects on aS aggregation in vitro and in cell models were 
studied. In particular, recombinants aS aggregation assays were performed in the 
presence of 14-3-3  isoform and the kinetic and the products of the process 
were studied using fluorescence spectroscopy, AFM and TEM. 14-3-3  was 
then overexpressed in the previously presented aS aggregation cell models, to 
evaluate cell viability and aS aggregation in the presence of the chaperone, and 
aS/14-3-3  interaction in a physiological environment. 
4.1 Fluorescence polarization spectroscopy and Thioflavin T 
kinetics of alpha-synuclein aggregation process 
Starting from the previously proposed interaction between aS and 14-3-3 
 (Sato et al., 2006), we purified both recombinant proteins from E. coli to 
performed in vitro assay on their putative interaction. The data published in the 
literature (Sato et al., 2006) and NMR experiments performed in our laboratory 
in the past years showed that the two recombinant proteins do not bind to each 
other, suggesting that the verified in cell interaction occurs after structural or 
post-translational modification of one or both proteins. Our hypothesis was that 
it can happen during aS oligomerization or aggregation. To test this idea we 
evaluated the effect exerted by 14-3-3  on the early steps of aS aggregation in 
vitro. To this aim we monitored the variation of the fluorescence polarization 
(FP) of an Oregon Green (OG) fluorescent probe covalently linked either to aS 
or to 14-3-3 at different time points in an aggregation assay, as proposed by 
Luk et al., 2007. The time dependences of the FP values, of both aS and 14-3-3 
 alone, were monitored in control experiments showing that aS forms 
oligomeric species and that 14-3-3  has not propensity to aggregate (Figure 4.1, 
panel A).  
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Figure 4.1 – A. Time course of aA aggregation process followed 
by FP of labeled aS 70 M (black) and labeled 14-3-3  17.5 M 
(red) as controls. FP of labeled aS 70 M in presence of 17.5 M 
14-3-3  (blue) and of aS 70 M in the presence of 17.5 M 
labeled 14-3-3  (green). 14-3-3  apparently inhibits aS 
fibrillization, while FP intensities increase with time when aS 
aggregates alone. FP values of aS monomers and 14-3-3  dimers 
seem to be comparable within the errors. 
 
However, we could not observe any significant increase in the FP value 
when aS aggregates in the presence of 14-3-3  at 4:1 stoichiometric ratio. This 
result suggests that the 14-3-3  hinders the formation of FP detectable aS 
oligomers. Identical results were obtained using either aS-OG or 14-3-3-OG as 
fluorescent probes (Figure 4.1, panel A).  The proceeding of the aggregation 
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process toward the formation of mature fibrils was monitored independently in a 
ThT assay. aS alone exhibited the expected behavior with the formation of ThT 
positive fibrils after 25 hours, whereas the addition of 14-3-3 (4:1 
stoichiometric ratio aS/14-3-3) resulted in a negligible increase in ThT 
fluorescence (Figure 4.1, panel B).  
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4.2 Alpha-synuclein and 14-3-3  aggregation products and 
morphology 
Based on these initial results, we decided to characterize not only the 
kinetic of the aggregation process, but also the aggregation products of aS:14-3-
3  by AFM.  Previous studies indicated that aS and 14-3-3 proteins are capable 
of forming soluble 54-83 kDa complexes that were suggested to mediate 
dopamine-dependent neurotoxicity in cultured neurons (Xu et al., 2002).  
In our hypothesis, these complexes could go undetected because of their 
dimensions in the FP and ThT previous presented kinetic assays, but not in a fine 
characterization performed by AFM. aS alone leads to the well characterized 
mature fibrils, with the expected distribution of height values (Figure 4.2, top 
raw), while a 4:1 stoichiometric ratio of aS:14-3-3  resulted in homogenous 
distribution of “curved objects” with a mean height of 2 nm and a morphology 
profoundly different from that of the mature fibrils (Figure 4.2, bottom raw).  A 
detailed analysis of the AFM images allowed a precise characterization of the 
curved objects: by sampling different aS:14-3-3   stoichiometric ratios, it was 
possible to correlate this parameter to both height and curvature of the end 
products. Incubation of aS with increasing amounts of 14-3-3 resulted in a shift 
toward a new population of curved objects significantly smaller in term of 
diameters than fibrils (Figure 4.2). In Figure 4.2 and Table 4.1 is reported the 
trend of both aS aggregates heights (middle column) and curvatures (right 
column) as a function of 14-3-3 relative concentration. 
 Moreover, this approach allowed to determine the aS:14-3-3 molar 
ratio of 30:1 as the minimal relative concentration of 14-3-3 required to 
achieve a detectable effect. These results were confirmed independently by TEM 
analysis, where the curved objects where compared to the canonical aS fibrils 
(Figure 4.3). 
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Figure 4.2 - AFM studies on morphology of aA aggregates, that are curved objects with 
smaller diameters compared to aS canonical fibrils in presence of 14-3-3  with respect to 
different 14-3-3  concentrations. Mean heights decrease with the increase of 14-3-3  
concentration, while mean curvatures of the curved objects increase with the chaperone 
concentration. 
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 No      
14-3-3 
30:1 24:1 20:1 12:1 7:1 4:1 
Heights 
(nm) 
7.3 2.8/7.6 - 2.5 2.0 2.3 1.9 
Standard 
deviation 
(nm) 
0.9 0.6/1.9 - 0.5 0.8 0.6 1.1 
Table 4.1 – Average heights estimated though a Gaussian fit of the distribution of heights 
derived from AFM images corresponding to the Figure 4.2. The values show the effects on 
aS fibrils heights as a function of 14-3-3  relative concentration. The stoichiometric ratio 
aS: 14-3-3  equal to 24:1 gave a distribution of heights to broaden to be fitted with a 
Gaussian, while the 30:1 showed a double peak, ascribed at least to two different species. 
 
 
 
Figure 4.3 - TEM images of aS fibrils (on the left) and curved objects (on the 
right) obtained respectively aggregating aS alone or in the presence of 14-3-3 
 (4:1 stechiometric ratio). The AFM results are confirmed by an independent 
technique. 
 
We further characterized these curved objects using immunogold 
labeling. We asked whether the effect of 14-3-3  on aS aggregation was due to 
a transient interaction or a stable binding between the two proteins. The 
observed homology between aS and 14-3-3  did not result in cross reactivity of 
the 14-3-3’s antibody toward aS.  Instead, 14-3-3  in solution could be 
efficiently detected by TEM using anti-14-3-3  antibody and dimeric gold 
particles could be occasionally detected (Figure 4.4, panel A). As shown in 
figure 4.4, panel B, immunogold with anti-14-3-3  of the aS:14-3-3  
aggregates revealed the highly specific placement of the gold nanoparticles on 
the curved objects, clearly indicating that the chaperone associates with aS to 
form novel oligomeric species.  
To investigate the secondary structure of the curved aS aggregates, after 
ThT assays, we used circular dichroism (CD). However, no information on the 
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aS component could be obtained from the CD spectra being the signal from aS 
aggregates significantly weaker compared to the intensity of 14-3-3  associated 
alpha-helical contribution. However, these data indicate that the 14-3-3  within 
the curved aggregation product maintains its folding. 
 
 
Figure 4.4 – A. Immuno-TEM images of 14-3-3  dimers in solution, where the gold 
nanoparticles represent a 14-3-3  molecule. The graph (on the right) shows the 
distances distribution in at least 10 images and highlight the presence of a peak 
corresponding to a plausible distance for a dimeric 14-3-3 molecule considering also 
the contribution due to the antibodies. 
B. Curved objects obtained aggregating aS in the presence of 14-3-3  
(stoichiometric ratio 4:1) imaged by immuno-TEM: the gold nanoparticles 
representing the chaperone molecules are on the aggregates, suggesting the 
formation of a stable complex. 
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4.3 14-3-3  effects on alpha-synuclein mature fibrils and seeding 
the aggregation with seeds in the presence of 14-3-3  
As previously mentioned, there is a lack of evidence of an interaction 
between aS and 14-3-3  in vitro. The interaction, at least from our experiments, 
seems to involve oligomeric aS during the aggregation process. To evaluate a 
further possible interaction between fibrillar aS and 14-3-3 , this isoform was 
added to preformed mature fibrils and samples were studied by AFM. As shown 
in Figure 4.5, the addition of a 1:4 molar excess of 14-3-3  to aS fibrils does 
not cause fibrils fragmentation or modify the morphology toward the curved 
object one, neither immediately nor after 72 hours of incubation. Therefore, we 
inferred that 14-3-3  is not likely to interact with mature fibrils and aS 
aggregation process is not reverted by 14-3-3  once the mature fibrils are 
already formed.  
 
 
Figure 4.5 - AFM micrographs of aS mature fibrils incubated with 
a 1:4 molar excess of 14-3-3  and observed immediately (on the 
right) or after 72 hours (on the left): no changes seem to occur 
because of the presence of the chaperone in aS fibrils 
characteristics. 
 
To evaluate if the interaction may also occur at later stages of the 
aggregation process, we analyzed the process of fibril elongation in the presence 
of 14-3-3  starting from preformed aS seeds (Wood et al., 1999).  The latter, 
are prepared by sonication of mature aS fibrils and act as nucleation centers for 
fibril growth (as reported in section 2.3.5 and discussed in chapter 3).  
Importantly, the sonication conditions affect the nature of the seeds obtained: 
AFM analysis allowed to classify seeds into two different types based on their 
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morphology, quantified as mean diameters: protofibrils fragments, with a 
diameter that is about 5 nm (type 1) and mature fibrils fragments, with an 
average diameter of 7 nm (type 2) (Figure 4.6). 
 
 
Figure 4.6 – A. Protofibrillar seeds (A) and fibrillar seeds (B) 
imaged by TEM (top) and AFM (bottom). The main different that is 
qualitatively evident from AFM images is the smaller length and 
diameters of the protofibrillar seeds compared to the fibrillar one. 
The quantification of this different was complicated by the presence 
of fragments of proteins due to the sonication that prevented the use 
of the available automatic recognition tool.  
 
The impact of 14-3-3  on aS aggregation was then analyzed in the 
presence of the different types of seeds. As showed by Giehm and co-workers, 
seeds act on the aggregation process by shortening the lag phase and increasing 
the slope of the rising part of the sigmoid growth of fibrils kinetic (Giehm et al., 
2011). Both protofibrillar and fibrillar seeds rapidly lead to the formation of m 
long mature fibrils when added to aS aggregation assays, but the line shapes of 
the aggregation curves are different when 14-3-3  is added to the mixture if we 
look at the obtained aggregation products.  
In our experiments, protofibrillar seeds (type 1) were less effective in   
promoting aS aggregation if 14-3-3  was present, suggesting that the chaperone 
can only hinder aS fibril elongation (Figure 4.7, panel A). On the contrary, 
fibrillar seeds (type 2) lead to the formation of mature fibrils comparable to the 
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one obtained in the absence of 14-3-3  even in the presence of 14-3-3 (Figure 
4.7, panel B).  
Furthermore, performing immuno-TEM experiments on these aggregates 
we found that 14-3-3 molecules were sequestered by the aggregation products 
leading to fibrils that include 14-3-3 molecules (Figura 4.7, panel C). We 
calculated the gold nanoparticles distances distribution and could not observe the 
presence of dimeric 14-3-3 (Figura 4.7, panel D) At this stage we cannot tell 
if this is either due to steric hindrance of the fibrils, which prevented the epitope-
antibody recognition, or to the different, non-dimeric conformation of 14-3-3  
within the aggregates. 
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Figure 4.7 - AFM and immuno-TEM micrographs of aS aggregation products of an aS 
aggregation assay promoted by the presence of two types of seeds (type 1 -protofibrillar- in 
panel A and type 2 -fibrillar- in panel B) in the presence of 14-3-3  (4:1 stechiometric 
ratio). While the presence of 14-3-3  when aggregation is promoted by type 1 seeds 
hampers fibrils formation (panel A), type 2 seeds promote fibrils formation even in the 
presence of the chaperone-like protein. C. 14-3-3  molecules represented by gold 
nanoparticles can be seen by immuno-TEM and remain trapped into the fibrils, but the 
nanoparticle distances distribution does not assess if 14-3-3  is present as a dimer or as a 
monomer.
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4.4 Specificity of  isoform effect on alpha-synuclein aggregation 
compared with the other 14-3-3 isoforms  
Several studies propose the family of 14-3-3 proteins to be involved in 
PD because of their presence in LBs (Kawamoto et al., 2002; Berg et al., 2003; 
Umahara et al., 2012), their capability of interacting with different PD related 
proteins (Li et al., 2011; Sato et al., 2006) and their ability to rescue toxicity in 
PD models (Yacoubian et al., 2010; Slone et al., 2011). However, several of the 
different isoforms were shown to be somehow involved at least in one of these 
processes, without giving any hints about the specificity of the involvement of 
the single isoform.  
For this reason and to verify is the effect we are observing is specific for 
 isoform, we performed AFM imaging on the aS aggregation products in the 
presence of the other six 14-3-3 isoforms. A representative AFM image for each 
isoform, along with the heights distribution of the obtained aggregates, is 
reported in Figure 4.8, From the images and the diameters evaluations reporter in 
Table 4.2, it is clear that among the 14-3-3 proteins only  and  induce the 
formation of curved objects instead of canonical fibrils. Moreover,  isoform 
lead to the formation of objects whose average diamters corresponds to the one 
of protofibrils. 
 
 No       
14-3-3 
      
Heights 
(nm) 
7.3 7.3 4.7 7.6 2.5 7.5 7.8 2.5 
Standard 
deviation 
(nm) 
4.1 3.7 1.7 1.4 1.2 1.9 5.2 1.2 
Table 4.2 – Average heights of fibrils or curved objects obtained aggregating aS and the 
different 14-3-3 isoforms.  The larger standard deviations compared to the one reported in 
Table 4.1 are due to the less consistent statistics. 
 
The results reported here suggest that the effect exerted by 14-3-3  is 
partially specific and dependent on specific structural features of this isoform. 
However, at this stage is difficult to speculate more on the observed specificity. 
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Figure 4.8 – Panel of AFM micrographs of aS aggregation products in the 
presence of different 14-3-3 isoforms and relative local heights distribution. 
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4.5 Effects of 14-3-3  on alpha-synuclein aggregation in cells 
To evaluate whether the effects of 14-3-3  on aS aggregation in vitro 
can be extended to a cellular contest, aS was overexpressed in HEK293 cells. 
Since aS overexpression by itself does not lead to the formation of large 
inclusions, we also reproduced the aS aggregation cellular model that was 
described in Section 3.1, in which aS fibrils formation was triggered by the 
presence of seeds introduced in cells overexpressing aS. After obtaining two 
different aS aggregation models (one for the study of the early aggregation steps 
and the other for the study of LBs-like inclusions formation), we overexpressed 
14-3-3  to investigate the effect of the chaperone on aS cellular phenotypes or 
inclusions characteristics. To make sure that the majority of cells overexpressing 
aS-EGFP was co-transfected with 14-3-3 , we tested different 14-3-3 :aS-
EGFP plasmid ratios using immunocytochemistry, and chose the one that lead us 
to have a very high level of coexpression (about 90% for a DNA ratio of 3:2).    
Figure 4.9 shows confocal microscopy images of cells overexpressing 
aS-EGFP and 14-3-3 in the absence or in the presence of exogenous aS seeds. 
14-3-3 co-localized with aS-EGFP in the cytoplasm, as expected, and could be 
also present in the aggregates formed after seeds triggering of aggregation 
(Figure 4.9, panel B). However, the limited resolution of confocal microscopy 
does not allow comparing the state of aS aggregation at the oligomeric level in 
the presence of 14-3-3  with respect to cells where only aS-EGFP was 
overexpressed (Figure 3.2). Therefore, we cannot rule out an interaction between 
oligomeric aS and 14-3-3 using this method. Sato et al., (2006) previously 
reported a strong interaction in HEK293 cells between the two proteins, using 
co-immunoprecipitation. However, co-immuniprecipitation cannot provide 
information on different possible aS oligomeric state. Further studies are needed 
to highlight the proposed interaction between aS oligomers and 14-3-3  in cell 
models. 
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Figure 4.9 – A. HEK293 cells overexpressing aS-EGFP and 14-3-3  and (B) 
overexpressing aS-EGFP and 14-3-3 , and treated with seeds. 14-3-3  was 
immunostained with polyclonal antibody against 14-3-3 proteins and a secondary 
antibody conjugated with Alexa Fluor 568). The green spots in panel B are aS 
aggregates, but a precise estimation of aggregates dimensions and amount is not 
feasible with conventional confocal microscopy techniques. 
 
We next assessed whether 14-3-3  overexpression is capable of 
preventing or reducing aS fibrils formation. As shown in figure 4.9, panel B, 
overexpression of 14-3-3  does not lead to a rescue of aggregation when aS was 
overexpressed in the presence of exogenous seeds. The latter result seems to be 
in good agreement with TEM experiments of aS fibrils formed in the presence of 
seeds and 14-3-3  in vitro.  One possibility is that seeds are too efficient in 
recruiting other building blocks on the growing fibers to be affected by the 
chaperone-like activity of 14-3-3 .  We could hypothesize that it can be trapped 
in within aS-EGFP aggregates, as reported above for recombinant 14-3-3  in 
seeds promoted aS fibrillation in vitro (Figure 4.7). The resolution limit of 
confocal microscopy, which is about 200-300 nm at this excitation wavelength, 
does not allow a fine morphological or dimensional comparison of aS-EGFP 
aggregates in the presence or absence of 14-3-3 , that we know from AFM 
measurement are between 2 and 8 nm in diameter and hundreds of nm in length. 
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4.6 14-3-3  effects on alpha-synuclein toxicity in cell models 
Considering that the effect 14-3-3  on the formation and on the 
dimensions of aS aggregates was difficult to quantify in cells and having in hand 
a robust cellular assay to monitor the toxicity of oligomeric and fibrillar aS, we 
next explored the effects of 14-3-3  overexpression on aS-EGFP aggregation-
mediated cellular toxicity. 
We used a very easily approachable readout, i.e. the quantification of cell 
survival in the presence of 14-3-3 , compared to control (EGFP transfected 
cells), after 12, 24 and 36 hours after aS-EGFP transfection, or aS-EGFP 
transfection and seeding (Figure 4.10).   
 
Figure 4.10 – Histograms representing the rescue due to 14-3-3  overexpression in 
cells overexpressing aA (A) or overexpressing aA plus seeding (B), and EGFP, as 
control (C). Fluorescent cells, overexpressing aA-EGFP or EGFP, were counted after 
12, 24 and 36 hours from transfection to evaluate cell viability in the presence or in 
the absence of 14-3-3  overexpression. After 24 and 36 hours 14-3-3  
overexpression rescues aS toxicity; the rescue takes also place when seeds are present, 
but only after 24 hours. In the control there is no rescue due to 14-3-3  
overexpression. 
We observed that overexpression of 14-3-3  rescued aS mediated 
toxicity in cells overexpressing aS-EGFP, at 24 and 36 hours (Figure 4.10, panel 
A) (respectively p=0.002 and p=0.02 when tested with Student’s test). On the 
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contrary, upon addition of seeds at the time of transfection, a statistically 
significant rescue effect was not detected neither at 24 hours nor at 36 hours 
(Figure 4.10, panel B).   As expected, the EGFP transfected cells, used as 
control, showed no rescue due to the overexpression of 14-3-3  (Figure 4.10, 
panel C). 
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4.7 14-3-3  sequestration by fibrils in alpha-synuclein 
aggregation cell model 
In a recent paper (Olzscha et al., 2011), it was proposed that one possible 
toxic mechanism for amyloidogenic chimeric proteins could be related to their 
ability of sequestering essential proteins from cells cytoplasm during 
aggregation. aS aggregation triggered by seeds in vitro leads to the formation of 
aS fibrils also in the presence of 14-3-3  molecules, which were sequestered 
into the aggregates, suggesting that also in this case a similar mechanism to the 
one proposed in the paper could occur.  
To verify this hypothesis we overexpressed aS, 14-3-3  and treated cells 
with seeds and checked the amount of soluble 14-3-3  in the cell cytoplasm by 
Western Blot. As control, we used cells not treated with seeds. 
Since 14-3-3  plasmid encoded for the protein fused with GST, it runs 
in the SDS page at a higher molecular weight compared with the endogenous 14-
3-3 proteins. Therefore, we were able to distinguish overexpressed 14-3-3  
from the endogenous 14-3-3 proteins when using an antibody against all the 
different 14-3-3 isoforms. As it is shown in figure 4.11, it is clear that when cells 
overexpressing aS are treated with seeds, a decrease in the amount of 
overexpressed 14-3-3  is shown by Western Blot analysis. This result could 
mean that 14-3-3  molecules are sequestered during aS aggregation by fibrils 
not only in vitro, but also in HEK293 cells. 
In a parallel experiment the enzyme β-galactosidase (LacZ gene) was 
overexpressed along with aS (with or without seeds treatment), to verify the 
specificity of the sequestration in this experimental conditions. Unfortunately, 
probably because of the molecular crowding in the cell cytoplasm induced by 
proteins overexpression, we found that the same sequestration occurs also for 
this protein that is totally PD non-associated and not of our interest. The same 
result was obtained overexpressing EGFP or the PD related protein LRRK2.  
For this reason this assay could not be used to verify overexpressed 14-3-
3  sequestration in cellular model in a specific manner.  
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Figure 4.11 – Western blot against LacZ and 14-3-3  in cells overexpressing aS and LacZ 
or 14-3-3 , or treated also with seeds. In cells treated with seeds a decrease in the soluble 
fraction of both LacZ and 14-3-3  can be seen, meaning probably that overexpression lead 
to molecular crowding that induces an aspecific protein sequestration. 
 
Therefore, we decided to look at the sequestration of endogenous 14-3-3 
 by Western Blot using a specific antibody against this isoform. We first 
checked the specificity of the antibody for this isoform using the recombinant 
14-3-3 proteins and the presence of the  isoform in a detectable amount in 
HEK293 cell line. 
Then seeds in different concentration (0.1, 0.25, 0.5 and 0.75 m) were 
used to trigger the aggregation in cells overexpressing aS. The idea was to see if 
different concentration of seeds could lead to an increased aggregation and to an 
increased sequestration of 14-3-3 . 
Looking at the amount of 14-3-3 in the cell cytoplasm in the different 
samples, compared to the control and to cells overexpressing aS, we found that 
14-3-3  expression in HEK293 was increased in cells only overexpressing aS.  
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Figure 4.12 - Relative densitometry graph and western blot representing the 
expression level of endogenous 14-3-3  with respect to GADPH, for cells 
overexpressing aS or/and treated with different amount of seeds. The variability in 
the results is probably due to the experimental conditions and to the method, but 
still a trend showing a decrease in soluble 14-3-3  present in cell cytoplasm can be 
seen as a function of the amount of seeds used for the treatment. 
 
This result is in good agreement with some experiments published 
recently on 14-3-3 proteins regulation in an A53T mice model (Kurz et al., 
2012). 
When also seeds are introduced, the trend of densitometry analysis 
shown in figure 4.12 suggests that there is a decrease in 14-3-3  amount present 
in the cell cytoplasm with respect to the increased concentration of seeds. 
However, repeating the experiment several times (n=4), it turned out that the 
decrease is not statistically significant, as it is clear from the histogram in figure 
4.12 and was evaluated by Student’s test. The reason has to be found in the 
variability of the method used to detect 14-3-3  amount in this experiment. 
Moreover, there are probably two competing mechanisms in the induced 
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variation of 14-3-3  expression in these cell models for aS aggregation. The 
first one is the up-regulation of 14-3-3  due to aS overexpression, while the 
second one is the sequestration of chaperone molecules into the aggregates. 
 
 
 
 
128 Chapter 4 
Results. Alpha-synuclein aggregation and 14-3-3 proteins  
  
4.8 14-3-3  and alpha-synuclein interaction in cell models 
Sato and co-workers proposed that aS and 14-3-3  can interact in cell 
models but not in vitro because of modification(s) that do not occur to 
recombinant proteins (Sato et al., 2006). They proved the interaction by co-
immunoprecipitation but not in live cells.  
For this reason and to verify the interaction of the two proteins in our 
cellular model we overexpressed aS-EGFP and 14-3-3 -dsRED in HEK293. 
We used cross-RICS to point out the presence of a complex constituted by the 
two proteins and cross-N&B method to evaluate its stoichiometry. 
A representative image of cells transfected with both aS-EGFP and 14-3-
3-dsRED is shown in Figure 4.13, panel A. To perform RICS analysis we 
needed a more zoomed-in image to reach the 50 nm pixel size necessary to 
obtain significant information of the interaction between the two proteins (Figure 
4.13, panel B). 
 
Figure 4.13 – A. Confocal images of HEK293 representative cell overexpressing 
aS-EGFP and 14-3-3 -dsRED. 
B. Particular of the cell presented in the panel B, on which cross-RICS and cross-
N&B analysis were performed (color scale, a. u.). 
 
Cross-RICS map of aS-EGFP and 14-3-3-dsRED is shown in Figure 
4.14 (panel A), where the colored peak in the center of the image represents the 
presence of an interaction between the two proteins. On the contrary, the cross-
RICS map of EGFP and dsRED calculated as a control is completely flat, 
meaning that no interaction occurs in this model between the two (Figure 4.14, 
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panel B). This result was also found for the other controls we performed, i.e. co-
expression of aS-EGFP and dsRED and co-expression of EGFP and 14-3-3-
dsRED. 
In Figure 4.14, panel C, we reported a tridimensional representation of 
the RICS map corresponding to the one shown in panel A and the associated 3D 
fit. Fitting this curve leaded to the estimation of the diffusion coefficient D for 
the complex constituted by aS and 14-3-3 . Repeating this estimation for 
different cells (n=10) in 3 different experiments allowed the calculation of the 
average diffusion coefficient of the complex that is D=0.47±0.05 m2/s. 
 
Figure 4.14 –Representative cross-RICS maps of a cell overexpressing both 
aS-EGFP and 14-3-3 -dsRED (A) or both EGFP and dsRED (B). The 
presence of the peak in the first map, whose tridimensional representation is 
reported in panel C, means that an interaction occurs. The fit of the 3D plot 
gives information about the diffusion process of the aS/14-3-3  complex. 
 
Interestingly the diffusion coefficients around this value usually account 
for membrane bound proteins or very large complexes. 
Since aS membrane binding propensity is very well known (Davidson et 
al., 1998; Bartels et al., 2010), a possible explanation is that the interaction 
occurs only between membrane bound aS, which acquires an alpha-helical 
structure, and 14-3-3  in the cytoplasm. Another possibility is that a large 
macromolecule is formed in the cytoplasm, because 14-3-3  molecules (and 14-
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3-3 proteins in general) are able to bind more than one protein. In this situation 
all the non-fluorescent proteins go undetected and therefore we are not able to 
asses, only from analysis, which hypothesis is the correct one. 
However, further analyses on these data were performed to obtain more 
information on the stoichiometry of the formed complex and on its localization. 
Cross-N&B method was used and cross-Brightness BCC was calculated 
for cells that showed an interaction between aS and 14-3-3  when RICS 
analysis was performed. 
Panel A in Figure 4.15 shows B1-B2 plot that presents all the possible 
brightnesses found in the image for the two different channels (and therefore for 
the two different proteins), corrected with a detrend filter that removes the 
contribution to the fluctuation due to slow movements. The red cursor position 
in the plot corresponds to the brightnesses of the monomeric EGFP and 
monomeric dsRED previously calibrated with the same method used for single 
channel N&B analysis (BEGFP=1.51±0.09 and BRFP=1.19±0.08). In the selection 
map (Panel A, on the left), pixels corresponding to those brightnesses are shown 
in the sample cell. 
However, B1-B2 plot does not give any hints about the formation of 
complexes: to obtain this information we calculated the BCC maps (Figure 4.15 
panel B) for the chosen representative cell versus B1 or B2. BCC map is slightly 
asymmetric, showing positive cross-variance and suggesting that at least in some 
regions the two proteins form complexes with a defined stoichiometric ratio. 
The red cursors allowed selecting the points with a positive cross-
correlation in the BCC map to show which are the pixels giving this signal in the 
selection map (Figure 4.15, panel B, on the right). As it is clear, most of the 
pixels showing positive cross brightness, which are the one presenting aS/14-3-
3 complexes, are located at the cellular membrane. This result suggests that the 
interaction in the cellular environment can occur mainly at the membranes, 
where aS acquires an alpha-helical conformation that may promote the binding 
between the two proteins. The purification of 14-3-3  from synaptic membranes 
from rat brain (Martin et al., 1994) and aS association to membranes at the 
presynaptic terminal reported in the literature further support this possibility. 
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Plotting aS-EGFP brightness and 14-3-3 -dsRED brightness in unit of 
monomer brightness lead to the construction of the stoichiometry map shown in 
Figure 4.16. Channel 1 axis shows the B value for aS, while channel 2 axis 
report the 14-3-3  brightness; in the z axis, each color represent the number of 
pixels that shows that pair of B values (color scale from light blue – few pixels- 
to red -many pixels-). The most populated region is the one corresponding to the 
maximum of the peak, which is located in position (0.99, 1. 58) for this cell. 
Averaging on several different cells (n>10) in 3 different experiments lead to the 
evaluation of the average stoichiometric ratio for the complex formed by the two 
proteins, that is 14-3-3 :aS =(1.5±0.3):(0.9±0.1). 14-3-3h is tipically dimeric, 
therefore we suggest that the interaction occurs between this dimer and aS 
monomer at the cellular membrane. The reason why the estimation for the 
number of 14-3-3  monomers constituting the complex is lower than two is 
probably due to the presence of endogenous 14-3-3 molecules that can 
contribute to the formation of the complex but are completely undetectable by 
cross-N&B analysis. 
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Figure 4.15 – A. B1-B2 map for a cell overexpressing both aS-EGFP and 14-3-3 -dsRED. 
In the selection map on the right the pixels in red are the pixels corresponding to the aS 
and 14-3-3  monomers selected through the cursor in the B1-B2 map.  
B. BCC versus B1 and B2 maps. In the selection maps on the right the pixels in red are the 
pixels corresponding to the aS and 14-3-3  complexes selected through the rectangular 
cursors in the asymmetric part of the relative BCC map. The localization clearly indicates 
that the complexes are mainly stacked at the plasma membrane. 
 
 
 
Results. Alpha-synuclein aggregation and 14-3-3 proteins  133 
Chapter 4 
 
Figure 4.16 – Stoichiometry map of the complexes detected by N&B method in cells 
overexpressing aS-EGFP and 14-3-3 -dsRED. The map shows that a complex constituted 
by 2 molecules of 14-3-3  (a dimer) and a single aS molecule is present in these cells. 
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4.9 Conclusions 
The results presented in this chapter show how 14-3-3  is able to 
interfere with aS aggregation process in vitro, probably interacting with aS 
oligomeric species, and leads to the formation of curved aggregates. These 
objects cannot be seen with the techniques available to us in cells overexpressing 
the two proteins.  
However, 14-3-3  overexpression in cells overexpressing aS leads to a 
rescue of the aS induced toxicity. We demonstrated that 14-3-3  can interact 
with aS in live cells, mainly at the plasma membrane, and probably this is 
associated to the reduced cell death that we observed. 
The presence of 14-3-3 h in aS aggregation assays triggered by seeds 
does not lead to any variation in the end products of the aggregation and amyloid 
fibrils that form in this case can sequester 14-3-3  molecules. Overexpressing 
14-3-3 h in cells in which aggregation is triggered by seeds does not cause any 
rescue in the induced toxicity and can lead to the sequestration of the molecular 
chaperone, too.  
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“Remember to look up at the stars and not down at your feet. 
Try to make sense of what you see and wonder about what 
makes the universe exist. Be curious. And however difficult 
life may seem, there is always something you can do and 
succeed at.  
It matters that you don't just give up.” 
 
Stephen Hawking 
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The results presented in this thesis are summarized in the schema below, 
which will be use as line of reasoning in the discussion. 
 
Schema 1.1 – aS oligomers were found in SH-SY5Y and HEK293 cells 
overexpressing aS: they induce cellular toxicity probably damaging 
mitochondrial membrane and inducing mitochondria fragmentation. We 
showed that aS oligomerization, but also the presence of aS fibrils or 
inclusions in cell cytoplasm, can affect NADH metabolism. This observation 
was done looking at the variation in the fluorescence properties (lifetime 
and emission spectrum maximum) of NADH in aS aggregation cell models 
and in vitro. 
aS aggregated in the presence of 14-3-3  lead to the formation of off-
pathway aggregates, i.e. curved objects, that contain both the proteins and 
whose morphological characteristics depends on the amount of 14-3-3  in 
the aggregation assay. Overexpressing the two proteins in HEK293 cells, we 
could not observe the formation of these complexes, but we measured a 
stable interaction between aS and 14-3-3  that seems to occur at the 
membranes. Very interestingly, 14-3-3  overexpression reduces cell death 
induced by aS overexpression.  
The use of seeds to promote aS aggregation in vitro lead to a faster 
formation of aS fibrils, while in cells it cause the assembly of aS fibrils and 
inclusions in cell cytoplasm and an increased cellular toxicity. 14-3-3  
presence in the aS aggregation assay in vitro does not hamper aS fibrils 
formation if seeds are present and 14-3-3  molecules are sequestered into 
amyloid fibrils. This sequestration occurs also in cells model, if aggregation 
is triggered by seeds. Considering the multiple cellular pathways in which 
14-3-3 h is involved, this evidence supports the idea of an increase of the 
toxic effects ascribed to aS aggregation, due to the lowered level of 
functional and available 14-3-3  in cell cytoplasm. 
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5.1 Alpha-synuclein aggregation in cell models  
The two cellular models used to study aS aggregation in cells were 
chosen to characterize two different aspects of the aggregation process: the early 
stages when aS assemblies into oligomeric species, and the latest part of the 
process, i. e. the formation of LBs-like inclusions. To study of aS 
oligomerization the protein was just overexpressed and the process was analysed 
by monitoring the fluorescence fluctuation of the EGFP fused with the proteins 
(N&B method). This method provides information on the concentration and on 
the average dimensions of aS oligomers. In both SH-SY5Y and HEK293 cell 
lines aS overexpression lead to the formation of a heterogeneous ensemble of 
oligomeric species when the protein reached at least the average concentration of 
80 M. aS oligomers are constituted by about 6±4 monomers, that is in good 
agreement with the most recent results on aS aggregation intermediate 
dimensions obtained by Cremades and co-workers in vitro (Cremades et al., 
2012). Moreover, aS oligomeric species were partially sequestered into 
lysosomes, suggesting that ALP activation may be induced by these potentially 
toxic species. The presence of aS oligomeric species in lysosomes in this cellular 
model is in good agreement with the previously published work by Mak et al., 
(2010) reporting the same mechanism active in a mice model. The idea that ALP 
starts to deal with oligomers that are potentially toxic was previously reported 
also by other groups (reviewed in Ebrahimi-Fakhari et al., 2012). 
A viability assay performed for this model, compared to EGFP 
transfected cells, showed that aS overexpression per se induce cell death. 
Therefore, we tried to identify a possible toxic mechanism of action for aS 
oligomers.  
Looking at mitochondria, we found that mitochondrial morphology and 
distribution in cells showing aS oligomeric species were altered. Mitochondrial 
fragmentation was probably due to the interaction between oligomeric aS and 
mitochondrial membranes as previously proposed but not experimentally proved 
in cells, by Nakamura et al., 2011. 
The chance of observing aS oligomeric species in live cells is important 
because it allows the association of new or previously proposed toxic 
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mechanism(s) to aS oligomers, as we did for mitochondria.  An issue remains 
open on the exact definition of the oligomeric aS. Among the several oligomers 
described in the literature, there are the oligomeric species found when 
aggregating aS in vitro, the oligomers that are found in the cells in pathological 
conditions and among those the oligomers that induce toxic effects and may be 
relevant to neurons death in parkinsonian brains. The oligomers we identified in 
our cell model are only one of the possible oligomeric species that aS can form; 
however, we believe that they are relevant considering their formation in a 
cellular milieu in live cells without any further treatment after aS 
overexpression. 
N&B method of revealing aS oligomeric species could be used to test 
the effectiveness of compounds able to interfere with aS aggregation process and 
toxicity. The study of aS oligomers in a cellular environment is important also 
for the characterization of the species and the mechanism(s) responsible for PD 
spread. It is clear from the published results (Desplats et al., 2009; Luk et al., 
2012) that there is a transfer of aS from unhealthy to healthy cells, but it has to 
be underlined the importance of the transmission not only of the misfolded 
material, but also of the associated structural information that probably causes 
the propagation of the aggregation process. N&B method, associated to particle 
tracking fluorescence techniques (Digman and Gratton, 2011) could be used to 
track the oligomers and the information that they carry, to develop possible 
therapeutic strategies based on the interference with the spreading mechanism.  
The second model provided a way to study LBs-like pathology in the 
cellular environment: simple aS overexpression does not lead to the formation of 
aS fibrils or large inclusions, whose assembly has to be triggered by the 
introduction, along with aS DNA during the transfection, of recombinant aS 
fibrils fragments in the cellular cytoplasm. This idea was first proposed by Luk 
et al., (2009) and the method allows the characterization of the final steps of the 
aggregation process. The same cell viability assay proposed for the cellular 
model discussed above showed that cell death under these conditions is even 
increased, probably as a result of multiple cell death mechanisms activated by aS 
overexpression and seeds introduction. The two of them could induce both aS 
fibrils formation, as shown by the data presented here and previously by other 
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groups (Luk et al., 2009; Danzer et al., 2009; Waxman et al., 2010), and 
oligomerization, mainly in those cells where seeds uptake is limited, but 
probably in all cells in which aS is overexpressed and a threshold concentration 
needed for self-assembly is reached. This results in a combined effect due to aS 
oligomers and larger aggregates that induce respectively apoptosis and necrosis 
(Nonaka et al., 2010). 
Considering the damages to mitochondria observed in the presence of 
aS oligomers in live cells, we hypothesized that NADH metabolism could be 
impaired in those cells. To quantify the differences in NADH metabolism in 
these two cell models compared with a control, we measured the variation of 
NADH fluorescence lifetime in live cells using the phasor fluorescence lifetime 
imaging method. 
Since NADH fluorescence emission spectrum partially overlaps with 
EGFP emission spectra, we moved to a plasmid overexpressing wild type aS 
without any tag. In both cell models, the one for the study of aS oligomerization 
and the one for the study of inclusions formation, NADH fluorescence lifetime 
was changed compared to the control. Average NADH lifetime in cells with aS 
oligomers or fibrils was consistently different from the average NADH lifetime 
of the control. This difference was more consistent when the average NADH 
lifetime was determined in cell cytoplasm, rather than in the whole cell, 
suggesting that variation in NADH characteristics are likely ascribed to 
mitochondrial NADH.     
In the images fluorescence spots characterized by very long lifetime 
were present in cells in these two cellular models, suggesting that the observed 
changes in NADH fluorescence properties may be due to a sequestration of 
NADH molecules by aS aggregates, as previously proved for other proteins 
oligomers (Jameson et al., 1989). To verify this idea, we measured fluorescence 
lifetime of aS aggregated in the presence of NADH in vitro and compared the 
results with free NADH, NADH bound to lactate dehydrogenase and NADH in 
solution with monomeric recombinant aS. Interestingly, fluorescence lifetime of 
NADH and aggregated aS show a variation toward larger values compatible with 
those measured in aS cell models; moreover, it seems that also monomeric aS 
induce a variation in NADH fluorescence lifetime, maybe through binding. 
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However, the variations of the NADH lifetime associated aS binding do not 
depend in a linear way from the dimensions of the species binding NADH and it 
is difficult to exactly correlate the dimension of the aggregates and the NADH 
lifetime values. 
Spectral phasor method allowed characterizing also the NADH 
fluorescence properties variation in term of emission spectrum maximum. The 
maximum for NADH spectrum when it was in the aggregates moved towards 
shorter wavelengths of about 4 nm with respect to free NADH in solution (from 
480.5 nm to 476.6 nm). This result is in good agreement with the estimation of 
the variation between free and bound NADH emission spectrum maxima (Palero 
et al., 2011). Moreover, this variation toward shorter wavelengths was reported 
for NADH spectra obtained from brain slices of mice model for Alzheimer 
disease, compared with NADH in solution (Büchner et al., 2002). The 
agreement between our data and the data published by Büchner et al., (2002)  
further underlines the importance of these findings not only in PD frame, but 
also as a general hints concerning NADH metabolism impairment in other 
neurodegenerative disorders.  
The possibility of using an intrinsic fluorescence source, i.e. NADH, to 
monitor aS oligomers and aggregates presence in cell models represents a new 
dye-free method to study this mechanism and the related toxicity. More 
importantly, the characterization of NADH fluorescence lifetime and spectra for 
the detection of aS aggregation could be applied also to animal models and in 
vivo, providing a new avenue of investigation through a useful and precise 
endogenous biomarker for the process. 
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5.2 Alpha-synuclein and 14-3-3  in vitro and in cell models 
The results presented in Chapter 4 show how 14-3-3  isoform, 
belonging to the 14-3-3 chaperone-like protein family, can interact with PD 
related protein aS. 
14-3-3  can interact with aS during aS aggregation in vitro, rerouting 
the process and leading to the formation of curved objects that are completely 
different in term of morphology from aS fibrils. Curved objects formed in the 
presence of the chaperone are due to a stable interaction between 14-3-3  and 
aS. Previous studies in our lab and published results (Sato et al., 2006), lead to 
the conclusion that the interaction between monomeric aS and dimeric 14-3-3  
in vitro does not occur. For this reason and considering the stable interaction that 
occurs during aS aggregation, we suggest that one of the possible aS species 
interacting with 14-3-3  are misfolded aS forms or aS oligomers.  
The curved objects show characteristics that are strongly dependent on 
the amount of 14-3-3  present in the aggregation assay. Moreover, they share 
some similarities in term of morphology with the aggregates formed by aS in the 
presence of other chaperones, as Hsp70 (Luk et al., 2008). 
Interestingly, these aS/14-3-3  aggregates are curved objects similar 
what was previously observed in aggregates obtained from Alzheimer -peptide 
aggregation, which forms fibrils and is linked to Alzheimer’s disease 
etiopathogenesis, in the presence of the protein serum amyloid P component 
(Janciauskiene et al., 1995). 
This evidence suggests that some of these chaperones, but also others 
(Bandopadhyay and de Belleroche, 2010) could act in a similar manner trying to 
interfere with aS aggregation process, and that this mechanism could be 
generalized to other amyloid fibrils forming proteins. 
In the case of 14-3-3 proteins, it seems from our data that the effect is 
exerted specifically by  and  isoforms, while  just partially interfere with the 
aggregation leading to the formation of objects with heights comparable to the 
one of aS protofibrils. The rationale of isoform specificity in effecting aS 
aggregation has to be searched with the structural differences among 14-3-3 
isoforms, in term of exposed hydrophobic patches and charged residues that 
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could mediate the interaction. However, considering the high sequence identity 
among the 14-3-3 proteins, the primary structure by itself could not account for 
their different propensity to interact with aS during the aggregation process. A 
more detailed comparative analysis of the ternary structure should be considered, 
taking into account also the great structural plasticity of aS and the further 
complexity deriving from the evolving quaternary structure of aS during the 
aggregation and in cellular environment. 
Accordingly, we could not observe the curved objects we found in vitro 
when we transfect 14-3-3  in cells overexpressing aS; however, we could 
identify a stable complex formed by aS monomer and 14-3-3  dimer, mainly 
localized at the plasma membrane. Therefore, it could be that the interaction 
occurs between a structured aS, which acquires an alpha-helical conformation 
when bound to the membrane (Davidson et al., 1998; Bartels et al., 2010), and 
dimeric 14-3-3 , which was also found associated to presynaptic membranes 
(Martin et al., 1994). This idea was also proposed for other 14-3-3 binding 
partners (Shikano et al., 2006).  
Another interesting idea that we could not verify is that the interaction 
between the two occurs when aS is phosphorylated at serine 87 and/or 129 
(Paleologou et al., 2010; Paleologou et al., 2008), given the propensity of 14-3-3 
proteins to bind phosphorylated motifs in their binding partners (Yang et al., 
2006). The proved interaction is in good agreement with the findings of Xu et 
al., (2002), that observed the presence of 14-3-3/aS complexes of 54-83 kDa in 
human primary neurons transfected with aS.  
The difficulties in the interpretation of the possible types of interaction 
between aS and 14-3-3 proteins suggest the need of detailed studies about the 
mechanism(s) of interactions based on the available tertiary structure of the two 
proteins. 
The overexpression of 14-3-3  in cells overexpressing aS induces a 
rescue in aS induced toxicity. This data, together with the fact that the two 
proteins interact in cells, suggests that the chaperone can be involved in 
maintaining aS in a non-toxic form, maybe preventing the conversion to 
aggregation-prone species. This idea is interestingly supported by the fact that in 
A53T transgenic mice models 14-3-3  was upregulated in the striatum (Kurz et 
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al., 2011), as if upregulation is the cellular response for maintaining aS in a non-
toxic form. 
To further investigate aS and 14-3-3  interaction and the ability of the 
chaperone of rescuing aS induced toxicity, we performed aggregation assays in 
vitro triggering aS aggregation with seeds in the presence of 14-3-3 . 
 14-3-3  was not able to interfere with fibrils formation process and the 
end products of the aggregation were mature fibrils containing 14-3-3  
molecules. This result, together with the fact the beyond a detectable threshold 
stoiochiometric ratio 14-3-3  is not able to reroute aS aggregation process 
toward the formation of curved objects, suggests that chaperone is limited in its 
effects by the amount of aS present in the aggregation assay. When aS amount is 
too high, 14-3-3  cannot deal with workload anymore and it is sequestered into 
the aggregates and fibrils. From the available immune-TEM data it is difficult to 
evaluate whether the 14-3-3  molecules in the fibrils maintain their folded and 
dimeric state or not. 
However, the sequestration of an essential protein for several cellular 
functions could be considered an additional toxic mechanism to be ascribed to 
aS aggregates, as suggested and proved in principle by Olzscha et al., (2011) for 
other chimeric amyloidogenic proteins. This idea could also be inferred from 
data published by Volpicelli-Daley et al., (2011): they show how synaptic 
proteins level in neurons cytoplasm is lowered in neurons treated with preformed 
fibrils and displaying aS aggregates.  
The facts that 14-3-3 proteins colocalizes with aS in A53T transgenic 
mice models (Shirakashi et al., 2006) and that 14-3-3 proteins can be found in 
LBs in parkinsonian brains (Kawamoto et al., 2002; Berg et al., 2003; Umahara 
et al., 2012) further support this idea.  
Moreover, as previously mentioned, 14-3-3  upregulation observed in 
A53T mice models (Kurz et al., 2011) could be seen as a cellular response also 
to the sequestration of 14-3-3  molecules by aS and the consequent reduced 
amount of molecular chaperone available in the cell cytoplasm. 
To prove the sequestration of 14-3-3  by aS aggreagates in cells we 
overexpressed the protein in cells in which overexpressed aS aggregation was 
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triggered by seeds. In good agreement with what we found in vitro, we could not 
measure a reduction in aS aggregates dimensions. However, we cannot conclude 
that no effects are exerted by 14-3-3  on aS fibrils in this model, because of the 
limited resolution of the confocal microscope compared to aS fibrils dimensions 
(200-300 nm of resolution versus fibrils with a diameter of about 7-10 nm and 
lengths of hundreds of nm or a few m). 
Moreover, 14-3-3  overexpression in this cellular model did not rescue 
aS aggregation induced toxicity, as it did in the other cell model. 
Measuring the amount of 14-3-3  in the cytoplasm of cells where aS 
aggregation is triggered by seeds, compared to cells where aS is only 
overexpressed, we found a reduction of the chaperone protein in solution. 
However, this reduction was also true for another overexpressed protein, the 
enzyme β-galactosidase, totally unrelated to PD. This suggests that the 
overexpression per se may lead to a certain degree of sequestration in a non-
specific manner, probably due to molecular crowding.  
For this reason, we evaluated the variation in the amount of endogenous 
soluble 14-3-3  in a cell model exposed to increasing amounts of seeds used to 
trigger the aggregation. The results show a high variability, but the trend 
suggests a decrease in the soluble 14-3-3  present in these cells, compared to 
the untreated control. 
The large dispersion in these data is probably due to the intrinsic 
variability of both the amount of overexpressed aS and the amount of up taken 
seeds. A further source of variability resides on the densitometry method used to 
evaluate the protein amount in the Western Blot. 
However, the variability could also be intrinsic: 14-3-3  could be 
upregulated at the level of the messenger RNA in response to the presence of 
aggregation prone aS, as seen in the A53T mice models (Kurz et al., 2011), 
determining an increase in the expressed protein. On the contrary, a decrease 
could be due to sequestration, determining the presence of two competing 
mechanisms acting on the detectable amount of 14-3-3  present in the cell 
cytoplasm. It will be interesting to study the amount of 14-3-3  messenger 
RNA, compared to a control, to test this latter hypothesis. 
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All together these results suggest that 14-3-3  is able to interfere with 
aS aggregation process until the amount of aS is not too high or the aggregation 
has proceeded too much; in that case, the protein is sequestered by aS 
aggregates, further increasing the aS related toxicity. Considering the broad 
range of functions that are ascribed to 14-3-3 proteins, further work is needed to 
understand if these chaperones could be used to conceive any therapeutic 
strategy to prevent aS aggregation or toxicity (Zhao et al., 2011).  
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